Richard Keefe - Publications

Affiliations: 
Duke Medical School, Durham, NC, United States 

414 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Eskridge CLM, Hochberger WC, Kaseda ET, Lencer R, Reilly JL, Keedy SK, Keefe RSE, Pearlson GD, Keshavan MS, Tamminga CA, Sweeney JA, Hill SK. Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders. Schizophrenia Research. 236: 54-60. PMID 34392106 DOI: 10.1016/j.schres.2021.07.036  1
2021 Turner TH, Atkins A, Keefe RSE. Virtual Reality Functional Capacity Assessment Tool (VRFCAT-SL) in Parkinson's Disease. Journal of Parkinson's Disease. PMID 34334421 DOI: 10.3233/JPD-212688  1
2021 Eum S, Hill SK, Alliey-Rodriguez N, Stevenson JM, Rubin LH, Lee AM, Mills LJ, Reilly JL, Lencer R, Keedy SK, Ivleva E, Keefe RSE, Pearlson GD, Clementz BA, Tamminga CA, et al. Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 34145405 DOI: 10.1038/s41386-021-01057-8  1
2021 Keefe RSE. Where do we cut the bell-shaped curve of CIAS? Schizophrenia Research. PMID 33618939 DOI: 10.1016/j.schres.2021.01.013  0.01
2021 Fleischhacker WW, Podhorna J, Gröschl M, Hake S, Zhao Y, Huang S, Keefe RSE, Desch M, Brenner R, Walling DP, Mantero-Atienza E, Nakagome K, Pollentier S. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. The Lancet. Psychiatry. 8: 191-201. PMID 33610228 DOI: 10.1016/S2215-0366(20)30513-7  1
2021 Seccomandi B, Agbedjro D, Bell M, Keefe RSE, Keshavan M, Galderisi S, Fiszdon J, Mucci A, Cavallaro R, Ojeda N, Peña J, Müller D, Roder V, Wykes T, Cella M. Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia. Schizophrenia Research. 228: 29-35. PMID 33429151 DOI: 10.1016/j.schres.2020.11.060  1
2020 Keefe RSE, Woods SW, Cannon TD, Ruhrmann S, Mathalon DH, McGuire P, Rosenbrock H, Daniels K, Cotton D, Roy D, Pollentier S, Sand M. A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale. Early Intervention in Psychiatry. PMID 33354862 DOI: 10.1111/eip.13083  1
2020 Kollins SH, DeLoss DJ, Cañadas E, Lutz J, Findling RL, Keefe RSE, Epstein JN, Cutler AJ, Faraone SV. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. The Lancet. Digital Health. 2: e168-e178. PMID 33334505 DOI: 10.1016/S2589-7500(20)30017-0  0.01
2020 Seccomandi B, Agbedjro D, Bell M, Keefe RSE, Keshavan M, Galderisi S, Fiszdon J, Mucci A, Cavallaro R, Bechi M, Ojeda N, Peña J, Wykes T, Cella M. Can IQ moderate the response to cognitive remediation in people with schizophrenia? Journal of Psychiatric Research. 133: 38-45. PMID 33307353 DOI: 10.1016/j.jpsychires.2020.12.013  1
2020 Cohen EA, Hassman HH, Ereshefsky L, Walling DP, Grindell VM, Keefe RSE, Wyka K, Horan WP. Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 33244149 DOI: 10.1038/s41386-020-00911-5  1
2020 Lim K, Smucny J, Barch DM, Lam M, Keefe RSE, Lee J. Cognitive Subtyping in Schizophrenia: A Latent Profile Analysis. Schizophrenia Bulletin. PMID 33098300 DOI: 10.1093/schbul/sbaa157  1
2020 Harvey PD, Horan WP, Atkins AS, Stevens H, Welch M, Yuan J, Patterson TL, Narasimhan M, Keefe RSE. Factor structure of cognitive performance and functional capacity in schizophrenia: Evidence for differences across functional capacity measures. Schizophrenia Research. PMID 32928621 DOI: 10.1016/J.Schres.2020.08.010  1
2020 Lindenmayer JP, Goldring A, Borne S, Khan A, Keefe RSE, Insel BJ, Thanju A, Ljuri I, Foreman B. Assessing instrumental activities of daily living (iADL) with a game-based assessment for individuals with schizophrenia. Schizophrenia Research. PMID 32690346 DOI: 10.1016/J.Schres.2020.07.001  1
2020 Keefe RSE, Green MF, Harvey PD. Requisite Skills and the Meaningful Measurement of Cognition. Jama Psychiatry. PMID 32639514 DOI: 10.1001/Jamapsychiatry.2020.1618  1
2020 Chaturvedi R, Kraus M, Keefe RSE. A new measure of authentic auditory emotion recognition: Application to patients with schizophrenia. Schizophrenia Research. PMID 32616360 DOI: 10.1016/j.schres.2019.11.043  1
2020 Goldberg TE, Harvey PD, Devanand DP, Keefe RSE, Gomar JJ. Development of an UPSA Short Form for Use in Longitudinal Studies in the Early Alzheimer's Disease Spectrum. The Journal of Prevention of Alzheimer's Disease. 7: 179-183. PMID 32463071 DOI: 10.14283/jpad.2019.51  1
2020 Ho NF, Lee BJ, Tng JX, Lam MZ, Chen G, Wang M, Zhou J, Keefe RS, Sim K. Cortico-limbic brain anomalies are associated with cognitive subtypes in psychosis: a longitudinal study. European Psychiatry : the Journal of the Association of European Psychiatrists. 1-31. PMID 32336305 DOI: 10.1192/J.Eurpsy.2020.36  1
2020 Kilciksiz CM, Keefe R, Benoit J, Öngür D, Torous J. Verbal memory measurement towards digital perspectives in first-episode psychosis: A review. Schizophrenia Research. Cognition. 21: 100177. PMID 32322540 DOI: 10.1016/J.Scog.2020.100177  0.01
2020 Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Calabrese JR, Sanacora G, Hermes G, Keefe RSE, Song A, et al. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nature Medicine. PMID 32231295 DOI: 10.1038/S41591-020-0806-7  1
2020 Kraus MS, Gold JM, Barch DM, Walker TM, Chun CA, Buchanan RW, Csernansky JG, Goff DC, Green MF, Jarskog LF, Javitt DC, Kimhy D, Lieberman JA, McEvoy JP, Mesholam-Gately RI, ... ... Keefe RSE, et al. The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. Schizophrenia Research. Cognition. 19: 100161. PMID 31832342 DOI: 10.1016/J.Scog.2019.100161  1
2020 Salgado JV, Carvalhaes CFR, Pires AM, Neves MCLD, Cruz BF, Cardoso CS, Lauar H, Teixeira AL, Keefe RSE. Sensitivity and applicability of the Brazilian version of the Brief Assessment of Cognition in Schizophrenia (BACS). Dementia & Neuropsychologia. 1: 260-265. PMID 29213399 DOI: 10.1590/S1980-57642008DN10300007  0.01
2020 Lindenmayer J, Khan A, Harvey P, Keefe R, Liharska L, Yavorsky C, Seddo M. M120. IMPAIRED CLINICAL INSIGHT AS A PREDICTOR OF RELAPSE IN SCHIZOPHRENIA Schizophrenia Bulletin. 46: S180-S181. DOI: 10.1093/Schbul/Sbaa030.432  0.04
2020 Kollins SH, DeLoss DJ, Cañadas E, Lutz J, Findling RL, Keefe RSE, Epstein JN, Cutler AJ, Faraone SV. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial The Lancet Digital Health. 2: e168-e178. DOI: 10.1016/s2589-7500(20)30017-0  0.01
2019 Rakesh G, Mischel NA, Luber B, Keefe RSE, Emory S, Lisanby SH, Szabo ST. Theta Burst for Cognitive Remediation in Schizophrenia: A Case Series and Feasibility Study. The Journal of Ect. PMID 31652174 DOI: 10.1097/Yct.0000000000000625  1
2019 Pani L, Keefe RSE. Approaches to attenuated psychosis syndrome treatments: A perspective on the regulatory issues. Schizophrenia Research. Cognition. 18: 100155. PMID 31431890 DOI: 10.1016/j.scog.2019.100155  1
2019 Harvey PD, Khan A, Atkins A, Walker TM, Keefe RSE. Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS). Schizophrenia Research. PMID 31196736 DOI: 10.1016/J.Schres.2019.05.040  1
2019 Ventura J, Welikson T, Ered A, Subotnik KL, Keefe RSE, Hellemann GS, Nuechterlein KH. Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning. Early Intervention in Psychiatry. PMID 31183960 DOI: 10.1111/Eip.12831  1
2019 Keefe RSE. Why are there no approved treatments for cognitive impairment in schizophrenia? World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 18: 167-168. PMID 31059617 DOI: 10.1002/wps.20648  0.01
2019 Mahncke HW, Kim SJ, Rose A, Stasio C, Buckley P, Caroff S, Duncan E, Yasmin S, Jarskog LF, Lamberti JS, Nuechterlein K, Strassnig M, Velligan D, Ventura J, Walker T, ... ... Keefe RSE, et al. Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. Schizophrenia Research. PMID 30930034 DOI: 10.1016/J.Schres.2019.03.006  1
2019 Harvey PD, Khan A, Atkins A, Keefe RS. Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes. Psychiatry Research. PMID 30679049 DOI: 10.1016/J.Psychres.2019.01.045  1
2019 Harvey P, Khan A, Atkins A, Keefe R. O5.7. VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT IN PATIENTS WITH SCHIZOPHRENIA: CORRELATES OF PERFORMANCE OF SOLITARY AND SOCIALLY RELEVANT TASKS Schizophrenia Bulletin. 45: S175-S175. DOI: 10.1093/Schbul/Sbz021.216  0.04
2019 Podhorna J, Hake S, Groeschl M, Pollentier S, Atkins A, Keefe R. S27. EFFICACY, SAFETY, AND PHARMACOKINETICS OF BI 425809 ONCE DAILY IN PATIENTS WITH SCHIZOPHRENIA: METHODOLOGY OF A RANDOMIZED TRIAL Schizophrenia Bulletin. 45: S315-S316. DOI: 10.1093/Schbul/Sbz020.572  0.01
2019 Kraus M, Walker T, Perkins D, Keefe R. T32. Intact Auditory Perception In Individuals At Clinical High Risk For Psychosis Schizophrenia Bulletin. 45. DOI: 10.1093/Schbul/Sbz019.312  1
2019 Welsh-Bohmer KA, Atkins AS, Plassman BL, Khan A, Chiang C, Culp M, O'Neil J, Walter R, Haneline S, Arbuckle J, Brewster S, Maruyama Y, Swanson T, Hayden KM, Romero H, ... Keefe RS, et al. O4-11-02: DEFINING COGNITION IN PRE-DEMENTIA CLINICAL TRIALS: BASELINE NEUROPSYCHOLOGICAL DATA FROM THE TOMMORROW STUDY Alzheimer's & Dementia. 15: P1262-P1262. DOI: 10.1016/J.Jalz.2019.06.4801  0.04
2019 Gomar JJ, Harvey PD, Devanand DP, Keefe RS, Goldberg TE. P2-463: DEVELOPMENT OF AN UPSA SHORT FORM FOR USE IN LONGITUDINAL STUDIES IN THE EARLY ALZHEIMER'S DISEASE SPECTRUM Alzheimer's & Dementia. 15: P794-P794. DOI: 10.1016/J.Jalz.2019.06.2870  0.12
2019 Podhorna J, Hake S, Zhao Y, Groeschl M, Pollentier S, Atkins A, Keefe R. P.244 Novel endpoints of motivation and reinforcement learning in a large interventional clinical trial of BI 425809 in patients with schizophrenia European Neuropsychopharmacology. 29: S187-S188. DOI: 10.1016/j.euroneuro.2019.09.286  0.01
2019 Krystal A, Pizzagalli D, Smoski M, Mathew S, Nurnberger J, Lisanby S, Iosifescu D, Murrough J, Weiner R, Calabrese J, Sanacora G, Keefe R, Song A, Goodman W, Szabo S, et al. 116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients Biological Psychiatry. 85: S48-S49. DOI: 10.1016/J.Biopsych.2019.03.130  0.01
2018 Krystal AD, Pizzagalli DA, Mathew SJ, Sanacora G, Keefe R, Song A, Calabrese J, Goddard A, Goodman W, Lisanby SH, Smoski M, Weiner R, Iosifescu D, Nurnberger J, Szabo S, et al. The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nature Reviews. Drug Discovery. 18: 82-84. PMID 30591715 DOI: 10.1038/Nrd.2018.222  1
2018 Keefe RSE, Pani L. Take This Cognitive Training Efficacy Bar Fight Outside (to a Regulatory Agency). Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. 3: 900-902. PMID 30409386 DOI: 10.1016/j.bpsc.2018.09.002  1
2018 Atkins AS, Khan A, Ulshen D, Vaughan A, Balentin D, Dickerson H, Liharska LE, Plassman B, Welsh-Bohmer K, Keefe RSE. Assessment of Instrumental Activities of Daily Living in Older Adults with Subjective Cognitive Decline Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). The Journal of Prevention of Alzheimer's Disease. 5: 216-234. PMID 30298179 DOI: 10.14283/jpad.2018.28  1
2018 Kraus MS, Walker TM, Jarskog LF, Millet RA, Keefe RSE. Basic auditory processing deficits and their association with auditory emotion recognition in schizophrenia. Schizophrenia Research. PMID 30268821 DOI: 10.1016/j.schres.2018.08.031  1
2018 Romero HR, Monsch AU, Hayden KM, Plassman BL, Atkins AS, Keefe RSE, Brewster S, Chiang C, O'Neil J, Runyan G, Atkinson MJ, Crawford S, Budur K, Burns DK, Welsh-Bohmer KA. TOMMORROW neuropsychological battery: German language validation and normative study. Alzheimer's & Dementia (New York, N. Y.). 4: 314-323. PMID 30094331 DOI: 10.1016/J.Trci.2018.06.009  0.01
2018 Lam M, Lee J, Rapisarda A, See YM, Yang Z, Lee SA, Abdul-Rashid NA, Kraus M, Subramaniam M, Chong SA, Keefe RSE. Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis. Jama Psychiatry. PMID 30046827 DOI: 10.1001/jamapsychiatry.2018.1668  1
2018 Fava M, Mahableshwarkar AR, Jacobson W, Zhong W, Keefe RS, Olsen CK, Jaeger J. What is the overlap between subjective and objective cognitive impairments in MDD? Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists. 30: 176-184. PMID 30028891  1
2018 Keefe RSE, Harvey PD, Khan A, Saoud JB, Staner C, Davidson M, Luthringer R. Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial. The Journal of Clinical Psychiatry. 79. PMID 29873956 DOI: 10.4088/Jcp.17M11753  1
2018 Yang Z, Lim K, Lam M, Keefe R, Lee J. Factor structure of the positive and negative syndrome scale (PANSS) in people at ultra high risk (UHR) for psychosis. Schizophrenia Research. PMID 29804925 DOI: 10.1016/J.Schres.2018.05.024  1
2018 Brown D, Nakagome K, Cordes J, Brenner R, Gründer G, Keefe RSE, Riesenberg R, Walling DP, Daniels K, Wang L, McGinniss J, Sand M. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Schizophrenia Bulletin. PMID 29718385 DOI: 10.1093/Schbul/Sby049  1
2018 Shafee R, Nanda P, Padmanabhan JL, Tandon N, Alliey-Rodriguez N, Kalapurakkel S, Weiner DJ, Gur RE, Keefe RSE, Hill SK, Bishop JR, Clementz BA, Tamminga CA, Gershon ES, Pearlson GD, et al. Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls. Translational Psychiatry. 8: 78. PMID 29643358 DOI: 10.1038/S41398-018-0124-8  1
2018 Xavier RM, Dungan JR, Keefe RSE, Vorderstrasse A. Polygenic signal for symptom dimensions and cognitive performance in patients with chronic schizophrenia. Schizophrenia Research. Cognition. 12: 11-19. PMID 29552508 DOI: 10.1016/j.scog.2018.01.001  1
2018 Keefe RSE, Nomikos G, Zhong W, Christensen MC, Jacobson W. A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction. The International Journal of Neuropsychopharmacology. PMID 29546401 DOI: 10.1093/Ijnp/Pyy020  1
2018 Liu S, Lee J, Tandi J, Wang C, Lim JKW, Ho N, Poh J, Alison Adcock R, Keefe R, Wood S, Krishnan R, Chee M, Zhou J. F156. LONGITUDINAL WORKING MEMORY FUNCTIONAL DYSCONNECTIVITY REFLECTS HETEROGENEITY IN INDIVIDUALS AT ULTRA HIGH RISK FOR PSYCHOSIS Schizophrenia Bulletin. 44: S281-S281. DOI: 10.1093/Schbul/Sby017.687  0.01
2018 Seccomandi B, Agbedjro D, Bell M, Keefe R, Keshavan M, Galderisi S, Medalia A, Fiszdon J, Maj M, Mucci A, Cavallato R, Wykes T, Cella M. T206. DOES AGE INFLUENCE RESPONSE TO COGNITIVE REMEDIATION? Schizophrenia Bulletin. 44: S196-S197. DOI: 10.1093/Schbul/Sby016.482  0.01
2018 Khan A, Liharska L, Harvey P, Atkins A, Keefe R, Ulshen D. T111. PANSS NEGATIVE SYMPTOM DIMENSIONS ACROSS GEOGRAPHICAL REGIONS: IMPLICATIONS FOR SOCIAL, LINGUISTIC AND CULTURAL CONSISTENCY Schizophrenia Bulletin. 44: S159-S159. DOI: 10.1093/Schbul/Sby016.387  0.01
2018 Ventura J, Welikson T, Subotnik KL, Ered A, Keefe R, Hellemann GH, Nuechterlein KH. T59. Virtual Realty Assessment Of Functional Capacity In Early Schizophrenia: Associations With Neurocognition, Functional Capacity Performance, And Daily Functioning Schizophrenia Bulletin. 44. DOI: 10.1093/Schbul/Sby016.335  1
2018 Chiang C, Alexander R, Welsh-Bohmer KA, Plassman BL, Romero H, Hayden KM, Keefe RS, Atkins AS, Harrigan P, O'Neil J, Culp M, Walter R, Wu J, Randle L, Haneline S, et al. P1-050: Adjudicating Mild Cognitive Impairment Due To Alzheimer'S Disease As A Novel Endpoint Event In The Tommorrow Study: A Delay-Of-Onset Phase 3 Clinical Trial Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.051  1
2018 Kollins SH, Bower J, Findling RL, Keefe R, Epstein J, Cutler AJ, White R, Aberle L, DeLoss D, Faraone SV. 2.40 A Multicenter, Randomized, Active-Control Registration Trial of Software Treatment for Actively Reducing Severity of ADHD (Stars-Adhd) to Assess the Efficacy and Safety of a Novel, Home-Based, Digital Treatment for Pediatric ADHD Journal of the American Academy of Child & Adolescent Psychiatry. 57: S172. DOI: 10.1016/J.Jaac.2018.09.128  0.01
2018 Sand M, Daniels K, Keefe R, Cordes J, Brenner R, Riesenberg R, Brown D, Nakagome K, Gründer G, Carter K, Walling D, Wang L. Effect of BI 409306 on Positive and Negative Syndrome Scale in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial Biological Psychiatry. 83. DOI: 10.1016/J.Biopsych.2018.02.542  1
2017 Khan A, Liharska L, Harvey PD, Atkins A, Ulshen D, Keefe RSE. Negative Symptom Dimensions of the Positive and Negative Syndrome Scale Across Geographical Regions: Implications for Social, Linguistic, and Cultural Consistency. Innovations in Clinical Neuroscience. 14: 30-40. PMID 29410935  1
2017 Harvey PD, Khan A, Keefe RSE. Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience. Innovations in Clinical Neuroscience. 14: 18-22. PMID 29410933  1
2017 Wang C, Lee J, Ho NF, Lim JKW, Poh JS, Rekhi G, Krishnan R, Keefe RSE, Adcock RA, Wood SJ, Fornito A, Chee MWL, Zhou J. Large-Scale Network Topology Reveals Heterogeneity in Individuals With at Risk Mental State for Psychosis: Findings From the Longitudinal Youth-at-Risk Study. Cerebral Cortex (New York, N.Y. : 1991). 1-10. PMID 29088373 DOI: 10.1093/Cercor/Bhx278  1
2017 Xavier RM, Vorderstrasse A, Keefe RSE, Dungan JR. Genetic correlates of insight in schizophrenia. Schizophrenia Research. PMID 29054485 DOI: 10.1016/j.schres.2017.10.021  1
2017 Healey KM, Penn DL, Perkins D, Woods SW, Keefe RSE, Addington J. Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction. Schizophrenia Bulletin. PMID 29036587 DOI: 10.1093/Schbul/Sbx080  1
2017 Ang MS, Abdul Rashid NA, Lam M, Rapisarda A, Kraus M, Keefe RSE, Lee J. The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia. Journal of Clinical Psychopharmacology. PMID 29016375 DOI: 10.1097/JCP.0000000000000790  1
2017 Blokland GAM, Del Re EC, Mesholam-Gately RI, Jovicich J, Trampush JW, Keshavan MS, DeLisi LE, Walters JTR, Turner JA, Malhotra AK, Lencz T, Shenton ME, Voineskos AN, Rujescu D, Giegling I, ... ... Keefe RSE, et al. The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project. Schizophrenia Research. PMID 28982554 DOI: 10.1016/J.Schres.2017.09.024  1
2017 Cella M, Stahl D, Morris S, Keefe RSE, Bell MD, Wykes T. Effects of cognitive remediation on negative symptoms dimensions: exploring the role of working memory. Psychological Medicine. 1-9. PMID 28866985 DOI: 10.1017/S0033291717000757  1
2017 Xavier RM, Pan W, Dungan JR, Keefe RSE, Vorderstrasse A. Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia. Schizophrenia Research. PMID 28693755 DOI: 10.1016/J.Schres.2017.07.002  1
2017 Keefe RSE, Davis VG, Harvey PD, Atkins AS, Haig GM, Hagino O, Marder S, Hilt DC, Umbricht D. Placebo Response and Practice Effects in Schizophrenia Cognition Trials. Jama Psychiatry. PMID 28636694 DOI: 10.1001/Jamapsychiatry.2017.1574  1
2017 Mazhari S, Ghafaree-Nejad AR, Soleymani-Zade S, Keefe RSE. Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia. Asian Journal of Psychiatry. 27: 12-15. PMID 28558882 DOI: 10.1016/j.ajp.2017.02.007  1
2017 Lam M, Wang M, Huang W, Eng GK, Rapisarda A, Kraus M, Kang S, Keefe RSE, Lee J. Establishing the Brief Assessment of Cognition - Short form. Journal of Psychiatric Research. 93: 1-11. PMID 28549241 DOI: 10.1016/j.jpsychires.2017.05.006  1
2017 Hochberger WC, Combs T, Reilly JL, Bishop JR, Keefe RSE, Clementz BA, Keshavan MS, Pearlson GD, Tamminga CA, Hill SK, Sweeney JA. Deviation from expected cognitive ability across psychotic disorders. Schizophrenia Research. PMID 28545944 DOI: 10.1016/J.Schres.2017.05.019  1
2017 Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, Haig G, Hilt DC, Dunayevich E, Umbricht D, Sand M, Keefe RSE. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. Schizophrenia Research. PMID 28433500 DOI: 10.1016/J.Schres.2017.03.040  1
2017 Kendler KS, Ohlsson H, Keefe RSE, Sundquist K, Sundquist J. The joint impact of cognitive performance in adolescence and familial cognitive aptitude on risk for major psychiatric disorders: a delineation of four potential pathways to illness. Molecular Psychiatry. 23: 1076-1083. PMID 28416810 DOI: 10.1038/mp.2017.78  0.01
2017 Eum S, Hill SK, Rubin LH, Carnahan RM, Reilly JL, Ivleva EI, Keedy SK, Tamminga CA, Pearlson GD, Clementz BA, Gershon ES, Keshavan MS, Keefe RS, Sweeney JA, Bishop JR. Cognitive burden of anticholinergic medications in psychotic disorders. Schizophrenia Research. PMID 28390849 DOI: 10.1016/J.Schres.2017.03.034  1
2017 Keefe RS, Kahn RS. Cognitive Decline and Disrupted Cognitive Trajectory in Schizophrenia. Jama Psychiatry. PMID 28329400 DOI: 10.1001/Jamapsychiatry.2017.0312  1
2017 Bishop J, Hill S, Mills L, Alliey-Rodriguez N, Reilly J, Shaffee R, McCarroll S, Keefe R, Pearlson G, Clementz B, Tamminga C, Keshavan M, Gershon E, Sweeney J. M94. Genetic Analyses of Cognitive Performance in Psychotic Disorders From the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Consortium Schizophrenia Bulletin. 43: S245-S245. DOI: 10.1093/Schbul/Sbx022.089  0.01
2017 Atkins A, Tseng T, Vaughan A, Harvey P, Narasimhan M, Patterson T, Khan A, Keefe R. M25. Development and Validation of the Brief Assessment of Validation in Schizophrenia (BAC-App) Schizophrenia Bulletin. 43: S220-S220. DOI: 10.1093/Schbul/Sbx022.024  0.01
2017 Keefe R, Woods S, Cannon T, Ruhrmann S, Mathalon D, McGuire P, Fillon G, Rosenbrock H, Sand M. M15. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306 Schizophrenia Bulletin. 43: S216-S217. DOI: 10.1093/Schbul/Sbx022.014  0.01
2017 Schooler N, Khan A, Keefe R, Robinson D, Kane J. 43. Cognitive Functioning in First-Episode Psychosis:_x000B_ Comparison of a 2-Year Coordinated Specialty Care Program to Community Care Schizophrenia Bulletin. 43. DOI: 10.1093/Schbul/Sbx021.062  1
2017 Marx C, Naylor J, Kilts J, Allan T, Smith K, Szabo S, Wagner R, Buchanan R, Keefe R, Shampine L. 19. Randomized Controlled Trial of a Neurosteroid Intervention in Schizophrenia Schizophrenia Bulletin. 43: S14-S14. DOI: 10.1093/Schbul/Sbx021.038  0.01
2017 Atkins AS, Khan A, Welsh-Bohmer KA, Plassman BL, Randolph C, Harrison J, Keefe RS. EXPANDING THE BRIEF ASSESSMENT OF COGNITION (BAC-APP) FOR ASSESSMENT OF COGNITION IN AGING: INITIAL FINDINGS FROM AN ONGOING NORMATIVE STUDY Alzheimer's & Dementia. 13: P1574-P1575. DOI: 10.1016/J.Jalz.2017.07.741  0.01
2017 Lam M, Keefe R, Liu JJ, Lee J. Pleiotropic Effects of Schizophrenia And Cognitive LOCI: A Meta-Analytic Approach European Neuropsychopharmacology. 27. DOI: 10.1016/J.Euroneuro.2016.09.432  1
2017 Lam M, Keefe R, Liu J, Lee J. 700. Genetic Overlaps between Schizophrenia and Cognition in Asia Biological Psychiatry. 81. DOI: 10.1016/J.Biopsych.2017.02.767  1
2017 Keefe R, Woods S, Cannon T, Ruhrmann S, Mathalon D, McGuire P, Fillon G, Rosenbrock H, Sand M. 868. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306 Biological Psychiatry. 81. DOI: 10.1016/J.Biopsych.2017.02.593  1
2016 Kraus M, Rapisarda A, Lam M, Thong JYJ, Lee J, Subramaniam M, Collinson SL, Chong SA, Keefe RSE. Disrupted latent inhibition in individuals at ultra high-risk for developing psychosis. Schizophrenia Research. Cognition. 6: 1-8. PMID 28740818 DOI: 10.1016/j.scog.2016.07.003  1
2016 Addington J, Liu L, Perkins DO, Carrion RE, Keefe RS, Woods SW. The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms. Schizophrenia Bulletin. PMID 27798225 DOI: 10.1093/Schbul/Sbw152  1
2016 Kantrowitz JT, Medalia A, Keefe RS, Harvey PD, Bruder G, Barch DM, Choo T, Lee S, Lieberman JA. Dr Kantrowitz and Colleagues Reply. The Journal of Clinical Psychiatry. 77: e1353. PMID 27788318 DOI: 10.4088/Jcp.16Lr10887A  1
2016 Atkins AS, Davis V, Tseng T, Vaughan A, Harvey P, Patterson T, Narasimhan M, Keefe RS. Validation of the tablet-administered Brief Assessment of Cognition (BAC App). Schizophrenia Research. PMID 27771201 DOI: 10.1016/J.Schres.2016.10.010  1
2016 Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 41: 2961. PMID 27725683 DOI: 10.1038/npp.2016.181  1
2016 Wang C, Ji F, Hong Z, Poh JS, Krishnan R, Lee J, Rekhi G, Keefe RS, Adcock RA, Wood SJ, Fornito A, Pasternak O, Chee MW, Zhou J. Disrupted salience network functional connectivity and white-matter microstructure in persons at risk for psychosis: findings from the LYRIKS study. Psychological Medicine. 1-13. PMID 27396386 DOI: 10.1017/S0033291716001410  1
2016 Reilly JL, Hill SK, Gold JM, Keefe RS, Clementz BA, Gershon E, Keshavan MS, Pearlson G, Tamminga CA, Sweeney JA. Impaired Context Processing is Attributable to Global Neuropsychological Impairment in Schizophrenia and Psychotic Bipolar Disorder. Schizophrenia Bulletin. PMID 27306316 DOI: 10.1093/Schbul/Sbw081  1
2016 Cruz BF, Resende CB, Carvalhaes CF, Cardoso CS, Teixeira AL, Keefe RS, Rocha FL, Salgado JV. Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999). 0. PMID 27304257 DOI: 10.1590/1516-4446-2015-1776  1
2016 Keefe RS, Davis VG, Atkins AS, Vaughan A, Patterson T, Narasimhan M, Harvey PD. Validation of a Computerized test of Functional Capacity. Schizophrenia Research. PMID 27091656 DOI: 10.1016/J.Schres.2016.03.038  1
2016 Lim J, Lee SA, Lam M, Rapisarda A, Kraus M, Keefe RS, Lee J. The relationship between negative symptom subdomains and cognition. Psychological Medicine. 1-9. PMID 27087476 DOI: 10.1017/S0033291716000726  1
2016 Kantrowitz JT, Sharif Z, Medalia A, Keefe RS, Harvey P, Bruder G, Barch DM, Choo T, Lee S, Lieberman JA. A multicenter, rater-blinded, randomized controlled study of auditory processing-focused cognitive remediation combined with open-label lurasidone in patients with schizophrenia and schizoaffective disorder. The Journal of Clinical Psychiatry. PMID 27035157 DOI: 10.4088/Jcp.15M09998  1
2016 Keefe RS, Reichenberg A. Predicting Schizophrenia. Jama Psychiatry. 73: 441-2. PMID 27028053 DOI: 10.1001/jamapsychiatry.2016.0138  1
2016 Keefe RS. Treating cognitive impairment in depression: an unmet need. The Lancet. Psychiatry. 3: 392-3. PMID 26995299 DOI: 10.1016/S2215-0366(16)00095-X  0.01
2016 Keefe RSE. Treating cognitive impairment in depression: An unmet need The Lancet Psychiatry. 3: 392-393. DOI: 10.1016/S2215-0366(16)00095-X  1
2016 Kraus M, Rapisarda A, Lam M, Thong JYJ, Lee J, Subramaniam M, Collinson SL, Chong SA, Keefe RSE. Disrupted latent inhibition in individuals at ultra high-risk for developing psychosis Schizophrenia Research: Cognition. 6: 1-8. DOI: 10.1016/j.scog.2016.07.003  1
2016 Welsh-Bohmer KA, Romero HR, Hayden KM, Plassman BL, Atkins AS, Turcotte N, Keefe RS, Makeeva OA, Zhukova NG, Monsch AU, Frisoni GB, Melikyan ZA, Brewster S, Chiang C, Maruyama Y, et al. Clinical Trials In The Preclinical To Mci Stages Of Ad: Cross-Cultural Validation And Normative Study Of The Tommorrow Neuropsychological Battery Alzheimers & Dementia. 12: 1189. DOI: 10.1016/J.Jalz.2016.07.140  1
2016 Khan A, Atkins AS, Stroescu I, Davis V, Williamson T, Mozley LH, Voss T, McMahon KB, Keefe RS. P4-291: Assessing the Impact of a Centralized Data Review on the Reliability of the Alzheimer’S Disease Assessment Scale-Cognitive (ADAS-COG) Alzheimer's & Dementia. 12: P1145-P1145. DOI: 10.1016/J.Jalz.2016.07.033  0.01
2015 Hochberger WC, Hill SK, Nelson CL, Reilly JL, Keefe RS, Pearlson GD, Keshavan MS, Tamminga CA, Clementz BA, Sweeney JA. Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives. Schizophrenia Research. PMID 26645510 DOI: 10.1016/J.Schres.2015.11.022  1
2015 Atkins AS, Stroescu I, Spagnola NB, Davis VG, Patterson TD, Narasimhan M, Harvey PD, Keefe RS. Assessment of Age-Related Differences in Functional Capacity Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). The Journal of Prevention of Alzheimer's Disease. 2: 121-127. PMID 26618145 DOI: 10.14283/jpad.2015.61  1
2015 Keefe RS, Harvey PD. Understanding Symbol Coding in Schizophrenia. Biological Psychiatry. 78: 744-6. PMID 26542742 DOI: 10.1016/J.Biopsych.2015.09.005  1
2015 McCleery A, Green MF, Hellemann GS, Baade LE, Gold JM, Keefe RS, Kern RS, Mesholam-Gately RI, Seidman LJ, Subotnik KL, Ventura J, Nuechterlein KH. Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB). Psychological Medicine. 1. PMID 26537981 DOI: 10.1017/S0033291715002433  1
2015 Keefe RS, Haig GM, Marder SR, Harvey PD, Dunayevich E, Medalia A, Davidson M, Lombardo I, Bowie CR, Buchanan RW, Bugarski-Kirola D, Carpenter WT, Csernansky JT, Dago PL, Durand DM, et al. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophrenia Bulletin. PMID 26362273 DOI: 10.1093/Schbul/Sbv111  1
2015 Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, Lombardo I, Hilt DC. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 3053-60. PMID 26089183 DOI: 10.1038/npp.2015.176  1
2015 Kelly DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Gold JM, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman SM, Russ JC, ... Keefe RS, et al. Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. Journal of Clinical Psychopharmacology. 35: 374-81. PMID 26082974 DOI: 10.1097/Jcp.0000000000000345  1
2015 Iwata Y, Nakajima S, Suzuki T, Keefe RS, Plitman E, Chung JK, Caravaggio F, Mimura M, Graff-Guerrero A, Uchida H. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Molecular Psychiatry. PMID 26077694 DOI: 10.1038/Mp.2015.68  1
2015 Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, Dvergsten C, Segreti AC, Beaver JS, Toler SM, Jett JE, Dunbar GC. Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. Schizophrenia Bulletin. PMID 26071208 DOI: 10.1093/schbul/sbv072  1
2015 Araújo GE, Resende CB, Cardoso AC, Teixeira AL, Keefe RS, Salgado JV. Validity and reliability of the Brazilian Portuguese version of the BACS (Brief Assessment of Cognition in Schizophrenia). Clinics (Sao Paulo, Brazil). 70: 278-82. PMID 26017795 DOI: 10.6061/clinics/2015(04)10  1
2015 Kristian Hill S, Buchholz A, Amsbaugh H, Reilly JL, Rubin LH, Gold JM, Keefe RS, Pearlson GD, Keshavan MS, Tamminga CA, Sweeney JA. Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extend beyond deficits predicted by generalized neuropsychological impairment. Schizophrenia Research. 166: 310-5. PMID 26008884 DOI: 10.1016/J.Schres.2015.05.018  1
2015 Harvey PD, Keefe RS. Methods for delivering and evaluating the efficacy of cognitive enhancement. Handbook of Experimental Pharmacology. 228: 5-25. PMID 25977078 DOI: 10.1007/978-3-319-16522-6_1  1
2015 McCleery A, Green MF, Hellemann GS, Baade LE, Gold JM, Keefe RS, Kern RS, Mesholam-Gately RI, Seidman LJ, Subotnik KL, Ventura J, Nuechterlein KH. Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB). Psychological Medicine. 1-10. PMID 25916421 DOI: 10.1017/S0033291715000641  1
2015 Lim J, Rekhi G, Rapisarda A, Lam M, Kraus M, Keefe RS, Lee J. Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS). Schizophrenia Research. 164: 8-14. PMID 25818728 DOI: 10.1016/j.schres.2015.03.007  1
2015 Klauser P, Zhou J, Lim JK, Poh JS, Zheng H, Tng HY, Krishnan R, Lee J, Keefe RS, Adcock RA, Wood SJ, Fornito A, Chee MW. Lack of Evidence for Regional Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings From the Longitudinal Youth at Risk Study. Schizophrenia Bulletin. PMID 25745033 DOI: 10.1093/Schbul/Sbv012  1
2015 Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, et al. A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophrenia Research. 164: 136-42. PMID 25728831 DOI: 10.1016/J.Schres.2015.01.041  1
2015 Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 2025-37. PMID 25687662 DOI: 10.1038/npp.2015.52  1
2015 Bauer IE, Ouyang A, Mwangi B, Sanches M, Zunta-Soares GB, Keefe RS, Huang H, Soares JC. Reduced white matter integrity and verbal fluency impairment in young adults with bipolar disorder: a diffusion tensor imaging study. Journal of Psychiatric Research. 62: 115-22. PMID 25684152 DOI: 10.1016/j.jpsychires.2015.01.008  1
2015 Healey KM, Combs DR, Gibson CM, Keefe RS, Roberts DL, Penn DL. Observable Social Cognition--A Rating Scale: an interview-based assessment for schizophrenia. Cognitive Neuropsychiatry. 20: 198-221. PMID 25675960 DOI: 10.1080/13546805.2014.999915  1
2015 Bauer IE, Keefe RS, Sanches M, Suchting R, Green CE, Soares JC. Evaluation of cognitive function in bipolar disorder using the Brief Assessment of Cognition in Affective Disorders (BAC-A). Journal of Psychiatric Research. 60: 81-6. PMID 25455513 DOI: 10.1016/j.jpsychires.2014.10.002  1
2015 Hill SK, Reilly JL, Ragozzino ME, Rubin LH, Bishop JR, Gur RC, Gershon ES, Tamminga CA, Pearlson GD, Keshavan MS, Keefe RS, Sweeney JA. Regressing to Prior Response Preference After Set Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP Study. Schizophrenia Bulletin. 41: 940-50. PMID 25194139 DOI: 10.1093/Schbul/Sbu130  1
2015 Lui S, Yao L, Xiao Y, Keedy SK, Reilly JL, Keefe RS, Tamminga CA, Keshavan MS, Pearlson GD, Gong Q, Sweeney JA. Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives. Psychological Medicine. 45: 97-108. PMID 25066779 DOI: 10.1017/S003329171400110X  1
2015 Keefe RS, Davis VG, Spagnola NB, Hilt D, Dgetluck N, Ruse S, Patterson TD, Narasimhan M, Harvey PD. Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 25: 176-84. PMID 25028065 DOI: 10.1016/J.Euroneuro.2014.06.009  1
2015 Yasuhiro Kaneda M, Keefe RS. An abbreviated version of the brief assessment of cognition in schizophrenia (BACS) The European Journal of Psychiatry. 29: 131-134. DOI: 10.4321/S0213-61632015000200004  0.01
2015 Jacobson W, Olsen C, Mahableshwarkar A, Yinzhong C, Keefe R. P.2.h.012 Effect of vortioxetine on functional capacity in patients with major depressive disorder with self-reported cognitive dysfunction European Neuropsychopharmacology. 25. DOI: 10.1016/S0924-977X(15)30622-2  1
2015 Atkins AS, Stroescu I, Davis V, Williamson T, Boyd K, Mozley LH, Voss T, Budd-McMahon K, Keefe RS. P4-299: Impact of expert data review and centralized scoring on test-retest reliability of the adas-cog Alzheimer's & Dementia. 11: P899-P900. DOI: 10.1016/j.jalz.2015.08.129  0.01
2014 Ethridge LE, Soilleux M, Nakonezny PA, Reilly JL, Hill SK, Keefe RS, Gershon ES, Pearlson GD, Tamminga CA, Keshavan MS, Sweeney JA. Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit. Schizophrenia Research. 159: 491-8. PMID 25261042 DOI: 10.1016/J.Schres.2014.08.025  1
2014 Gray BE, McMahon RP, Green MF, Seidman LJ, Mesholam-Gately RI, Kern RS, Nuechterlein KH, Keefe RS, Gold JM. Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery. Schizophrenia Research. 159: 182-7. PMID 25156338 DOI: 10.1016/J.Schres.2014.07.032  1
2014 Hufford MR, Davis VG, Hilt D, Dgetluck N, Geffen Y, Loebel A, Haig G, Santarelli L, Keefe RSE. Circadian rhythms in cognitive functioning among patients with schizophrenia: Impact on signal detection in clinical trials of potential pro-cognitive therapies Schizophrenia Research. 159: 205-210. PMID 25108773 DOI: 10.1016/j.schres.2014.07.018  1
2014 Keefe RS, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M. Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. The Journal of Clinical Psychiatry. 75: 864-76. PMID 25099527 DOI: 10.4088/Jcp.13R08609  1
2014 Ruse SA, Harvey PD, Davis VG, Atkins AS, Fox KH, Keefe RS. Virtual Reality Functional Capacity Assessment In Schizophrenia: Preliminary Data Regarding Feasibility and Correlations with Cognitive and Functional Capacity Performance. Schizophrenia Research. Cognition. 1: e21-e26. PMID 25083416 DOI: 10.1016/J.Scog.2014.01.004  1
2014 Keefe RSE. Cognition and motivation as treatment targets in schizophrenia Jama Psychiatry. 71: 987-988. PMID 25075711 DOI: 10.1001/jamapsychiatry.2014.1281  1
2014 Lam M, Collinson SL, Eng GK, Rapisarda A, Kraus M, Lee J, Chong SA, Keefe RS. Refining the latent structure of neuropsychological performance in schizophrenia. Psychological Medicine. 44: 3557-70. PMID 25066336 DOI: 10.1017/S0033291714001020  1
2014 Marx CE, Lee J, Subramaniam M, Rapisarda A, Bautista DC, Chan E, Kilts JD, Buchanan RW, Wai EP, Verma S, Sim K, Hariram J, Jacob R, Keefe RS, Chong SA. Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology. 231: 3647-62. PMID 25030803 DOI: 10.1007/s00213-014-3673-4  1
2014 Keefe RS, Fox KH, Davis VG, Kennel C, Walker TM, Burdick KE, Harvey PD. The Brief Assessment of Cognition In Affective Disorders (BAC-A):performance of patients with bipolar depression and healthy controls. Journal of Affective Disorders. 166: 86-92. PMID 25012414 DOI: 10.1016/J.Jad.2014.05.002  1
2014 Keefe RSE. The longitudinal course of cognitive impairment in schizophrenia: An examination of data from premorbid through posttreatment phases of illness Journal of Clinical Psychiatry. 75: 8-13. PMID 24919165 DOI: 10.4088/JCP.13065su1.02  1
2014 Rapisarda A, Kraus M, Tan YW, Lam M, Eng GK, Lee J, Subramaniam M, Collinson SL, Chong SA, Keefe RS. The continuous performance test, identical pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore. Schizophrenia Research. 156: 233-40. PMID 24819191 DOI: 10.1016/j.schres.2014.04.016  1
2014 Ruse SA, Davis VG, Atkins AS, Krishnan KR, Fox KH, Harvey PD, Keefe RS. Development of a virtual reality assessment of everyday living skills. Journal of Visualized Experiments : Jove. PMID 24798174 DOI: 10.3791/51405  1
2014 Yong E, Barbato M, Penn DL, Keefe RS, Woods SW, Perkins DO, Addington J. Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis. Psychiatry Research. 218: 39-43. PMID 24755041 DOI: 10.1016/J.Psychres.2014.04.003  1
2014 Graham KA, Keefe RS, Lieberman JA, Calikoglu AS, Lansing KM, Perkins DO. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Intervention in Psychiatry. PMID 24612563 DOI: 10.1111/Eip.12122  1
2014 Mazhari S, Parvaresh N, Eslami Shahrbabaki M, Sadeghi MM, Nakhaee N, Keefe RS. Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls. Psychiatry and Clinical Neurosciences. 68: 160-6. PMID 24552637 DOI: 10.1111/pcn.12107  1
2014 Umbricht D, Keefe RS, Murray S, Lowe DA, Porter R, Garibaldi G, Santarelli L. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 39: 1568-77. PMID 24549101 DOI: 10.1038/npp.2014.17  1
2014 Madhoo M, Keefe RS, Roth RM, Sambunaris A, Wu J, Trivedi MH, Anderson CS, Lasser R. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 39: 1388-98. PMID 24309905 DOI: 10.1038/Npp.2013.334  1
2014 Reilly JL, Frankovich K, Hill S, Gershon ES, Keefe RS, Keshavan MS, Pearlson GD, Tamminga CA, Sweeney JA. Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories. Schizophrenia Bulletin. 40: 1011-21. PMID 24080895 DOI: 10.1093/Schbul/Sbt132  1
2014 Meier MH, Caspi A, Reichenberg A, Keefe RS, Fisher HL, Harrington H, Houts R, Poulton R, Moffitt TE. Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study. The American Journal of Psychiatry. 171: 91-101. PMID 24030246 DOI: 10.1176/Appi.Ajp.2013.12111438  1
2014 Dandash O, Fornito A, Lee J, Keefe RS, Chee MW, Adcock RA, Pantelis C, Wood SJ, Harrison BJ. Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis. Schizophrenia Bulletin. 40: 904-13. PMID 23861539 DOI: 10.1093/schbul/sbt093  1
2014 Bauer I, Keefe R, Suchting R, Green C, Zunta-Soares G, Soares J. The brief assessment of cognition in affective disorders (BAC-A): a new instrument for assessing cognitive functioning in bipolar disorder F1000research. 5. DOI: 10.7490/F1000Research.1095519.1  1
2014 Lam M, See AY, Lee J, Kang S, Rapisarda A, Kraus M, Keefe R, Collinson S. Poster #T129 NEUROCOGNITIVE ARCHITECTURE OF SCHIZOTYPY IN AN ASIAN POPULATION Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70946-6  1
2014 Hilt D, Lombardo I, Gawryl M, Dgetluck N, Keefe R. Poster #T94 OPTIMIZING TREATMENT AND SIGNAL DETECTION WITH EVP-6124 IN A CIAS PHASE 2B STUDY Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70911-9  1
2014 Lam M, Collinson S, Eng GK, Rapisarda A, Kraus M, Lee J, Chong SA, Keefe R. Poster #M186 NEUROCOGNITIVE ARCHITECTURE OF SCHIZOPHRENIA Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70736-4  1
2014 Huang W, Lee J, Lam M, Rapisarda A, Kraus M, Keefe R. Poster #S188 THE ROLE OF COGNITIVE RESERVE IN PREDICTING NEUROPSYCHOLOGICAL OUTCOME IN SCHIZOPHRENIA Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70467-0  1
2014 Kelly DL, Sullivan KM, Wehring HJ, McEvoy JP, Keefe R, McMahon RP, Gold JM, Feldman S, Warfel C, Kearns AM, Osing J, Russ J, Vyas G, Richardson CM, August S, et al. Adjunctive Minocycline In Clozapine Treated Schizophrenia Patients Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70257-9  1
2014 Kane J, Keefe R. Update On Therapeutics: Improving The Clinical Yield Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70134-3  1
2014 Adcock RA, MacInnes J, Murty V, Ballard I, Chong SA, Subramaniam M, Keefe R, MacDuffie K, Poh J, Dorairaj K, Thong J, Bong Y. DORSOLATERAL PREFRONTAL CORTEX DRIVES MESOLIMBIC DOPAMINERGIC REGIONS DURING MOTIVATED BEHAVIOR: INSIGHTS FROM DYNAMIC CAUSAL MODELING AND FMRI IN AT-RISK ADOLESCENTS Schizophrenia Research. 153: S38. DOI: 10.1016/S0920-9964(14)70127-6  0.01
2014 Keefe RS, Moghaddam B, McGuire P. REWARD PROCESSING, COGNITION AND PERCEPTION DURING ADOLESCENT BRAIN DEVELOPMENT AND VULNERABILITY FOR PSYCHOSIS Schizophrenia Research. 153: S37-S38. DOI: 10.1016/S0920-9964(14)70124-0  0.01
2014 Atkins AS, Keefe RS, Vaughan AW, Turcotte NM, Makeeva OA, Monsch AU, Frisoni GB, Parapini M, Melikyan ZA, Brewster S, O'Neil J, Schuster J, Lymboura M, Romero H, Hayden KM, et al. P3-255: CULTURAL ADAPTATION OF TRANSLATED NEUROCOGNITIVE ASSESSMENTS IN RUSSIA, SWITZERLAND AND ITALY: PILOT TESTING FOR A PROGRAM TO DELAY THE ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE Alzheimer's & Dementia. 10: P725-P726. DOI: 10.1016/J.Jalz.2014.05.1347  0.01
2014 Welsh-Bohmer KA, Romero HR, Hayden KM, Plassman BL, Atkins AS, Vaughan AW, Turcotte N, Keefe RS, Makeeva O, Monsch AU, Frisoni GB, Melikyan Z, Brewster SR, Chiang C, O'Neil J, et al. P2-392: CROSS-CULTURAL VALIDATION AND NORMATIVE STUDY OF A NEUROPSYCHOLOGICAL BATTERY USED IN THE DETERMINATION OF CLINICAL ENDPOINTS TO DELAY ONSET OF MCI Alzheimer's & Dementia. 10: P622-P623. DOI: 10.1016/J.Jalz.2014.05.1072  0.04
2013 Kim JL, Rele S, Marks DM, Masand PS, Yerramsetty P, Millet RA, Keefe RS, Patkar AA. Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial. The Primary Care Companion For Cns Disorders. 15. PMID 24800123 DOI: 10.4088/PCC.13m01555  1
2013 Lee TS, Goh SJ, Quek SY, Phillips R, Guan C, Cheung YB, Feng L, Teng SS, Wang CC, Chin ZY, Zhang H, Ng TP, Lee J, Keefe R, Krishnan KR. A brain-computer interface based cognitive training system for healthy elderly: a randomized control pilot study for usability and preliminary efficacy. Plos One. 8: e79419. PMID 24260218 DOI: 10.1371/Journal.Pone.0079419  1
2013 Lee J, Rekhi G, Mitter N, Bong YL, Kraus MS, Lam M, Rapisarda A, Lee TS, Subramaniam M, Chong SA, Keefe RS. The Longitudinal Youth at Risk Study (LYRIKS)--an Asian UHR perspective. Schizophrenia Research. 151: 279-83. PMID 24139196 DOI: 10.1016/j.schres.2013.09.025  1
2013 Rashid NA, Lim J, Lam M, Chong SA, Keefe RS, Lee J. Unraveling the relationship between obesity, schizophrenia and cognition. Schizophrenia Research. 151: 107-12. PMID 24119725 DOI: 10.1016/j.schres.2013.09.020  1
2013 Yaakub SN, Dorairaj K, Poh JS, Asplund CL, Krishnan R, Lee J, Keefe RS, Adcock RA, Wood SJ, Chee MW. Preserved working memory and altered brain activation in persons at risk for psychosis. The American Journal of Psychiatry. 170: 1297-307. PMID 24077560 DOI: 10.1176/Appi.Ajp.2013.12081135  1
2013 Meier MH, Shalev I, Moffitt TE, Kapur S, Keefe RS, Wong TY, Belsky DW, Harrington H, Hogan S, Houts R, Caspi A, Poulton R. Microvascular abnormality in schizophrenia as shown by retinal imaging. The American Journal of Psychiatry. 170: 1451-9. PMID 24030514 DOI: 10.1176/Appi.Ajp.2013.13020234  1
2013 Marder SR, Alphs L, Anghelescu IG, Arango C, Barnes TR, Caers I, Daniel DG, Dunayevich E, Fleischhacker WW, Garibaldi G, Green MF, Harvey PD, Kahn RS, Kane JM, Keefe RS, et al. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia Research. 150: 328-33. PMID 24028744 DOI: 10.1016/J.Schres.2013.07.058  1
2013 Barbato M, Liu L, Penn DL, Keefe RS, Perkins DO, Woods SW, Addington J. Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis. Schizophrenia Research. 150: 542-6. PMID 24012459 DOI: 10.1016/J.Schres.2013.08.015  1
2013 Kahn RS, Keefe RS. Schizophrenia is a cognitive illness: time for a change in focus. Jama Psychiatry. 70: 1107-12. PMID 23925787 DOI: 10.1001/Jamapsychiatry.2013.155  1
2013 Eng GK, Lam M, Bong YL, Subramaniam M, Bautista D, Rapisarda A, Kraus M, Lee J, Collinson SL, Chong SA, Keefe RS. Brief assessment of cognition in schizophrenia: normative data in an English-speaking ethnic Chinese sample. Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists. 28: 845-58. PMID 23912998 DOI: 10.1093/arclin/act060  1
2013 Keefe RS, Kraemer HC, Epstein RS, Frank E, Haynes G, Laughren TP, McNulty J, Reed SD, Sanchez J, Leon AC. Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials. Innovations in Clinical Neuroscience. 10: 4S-19S. PMID 23882433  1
2013 Hill SK, Reilly JL, Keefe RS, Gold JM, Bishop JR, Gershon ES, Tamminga CA, Pearlson GD, Keshavan MS, Sweeney JA. Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. The American Journal of Psychiatry. 170: 1275-84. PMID 23771174 DOI: 10.1176/Appi.Ajp.2013.12101298  1
2013 Nutt D, Gispen-de Wied CC, Arango C, Keefe RS, Penadés R, Murphy DG, Robbins TW, Sahakian BJ. Cognition in schizophrenia: summary Nice Consultation Meeting 2012. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 769-78. PMID 23684476 DOI: 10.1016/J.Euroneuro.2013.03.005  1
2013 Vita A, Deste G, Barlati S, De Peri L, Giambra A, Poli R, Keefe RS, Sacchetti E. Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. Schizophrenia Research. 146: 217-23. PMID 23510596 DOI: 10.1016/j.schres.2013.02.035  1
2013 Rapisarda A, Lim TF, Lim M, Collinson SL, Kraus MS, Keefe RS. Applicability of the MATRICS Consensus Cognitive Battery in Singapore. The Clinical Neuropsychologist. 27: 455-69. PMID 23362823 DOI: 10.1080/13854046.2012.762120  0.01
2013 Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 1245-52. PMID 23325325 DOI: 10.1038/Npp.2013.23  1
2013 Barbato M, Colijn MA, Keefe RS, Perkins DO, Woods SW, Hawkins KA, Christensen BK, Addington J. The course of cognitive functioning over six months in individuals at clinical high risk for psychosis. Psychiatry Research. 206: 195-9. PMID 23159196 DOI: 10.1016/J.Psychres.2012.10.013  1
2013 Lam M, Eng GK, Rapisarda A, Subramaniam M, Kraus M, Keefe RS, Collinson SL. Formulation of the age-education index: measuring age and education effects in neuropsychological performance. Psychological Assessment. 25: 61-70. PMID 23148648 DOI: 10.1037/a0030548  1
2013 Cruz BF, de Resende CB, Abreu MN, Rocha FL, Teixeira AL, Keefe RS, Salgado JV. How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS. Cognitive Neuropsychiatry. 18: 243-51. PMID 23145794 DOI: 10.1080/13546805.2012.730995  1
2013 Ventura J, Reise SP, Keefe RS, Hurford IM, Wood RC, Bilder RM. The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition. Schizophrenia Bulletin. 39: 583-91. PMID 22328641 DOI: 10.1093/Schbul/Sbs001  1
2013 Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophrenia Bulletin. 39: 564-74. PMID 22290266 DOI: 10.1093/schbul/sbr189  1
2013 Keefe RSE, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: What have we learned so far? Schizophrenia Bulletin. 39: 417-435. PMID 22114098 DOI: 10.1093/schbul/sbr153  1
2013 Chia YY, Hong Z, Lee J, Yaakub SN, Poh JS, Krishnan R, Keefe RS, Adcock RA, Wood SJ, Chee MW, Zhou J. Reduced anatomical and functional connectivity of the salience network in persons at-risk for psychosis F1000research. 4. DOI: 10.7490/F1000Research.1093611.1  1
2013 Abdullah H. Reliability and Validity of the Malay Version of the Brief Assessment of Cognition in Schizophrenia (BACS): Preliminary Results The European Journal of Social & Behavioural Sciences. 5: 920-926. DOI: 10.15405/EJSBS.66  0.01
2013 Keefe R, Mahableshwarkar A, Olsen C. P.2.f.013 Clinical evidence for improvement in cognitive dysfunction in patients with major depressive disorder (MDD) after treatment with vortioxetine European Neuropsychopharmacology. 23: S402-S403. DOI: 10.1016/S0924-977X(13)70636-9  0.04
2013 Hufford M, Davis V, Dgetluck N, Gawryl M, Hilt D, Rappaport A, Keefe R. Circadian rhythms in cognitive functioning: Impact on signal detection in clinical trials of pro-cognitive therapies Alzheimers & Dementia. 9: 298. DOI: 10.1016/J.Jalz.2013.05.607  1
2012 Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. BL-1020, a new γ-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study Journal of Clinical Psychiatry. 73. PMID 23059159 DOI: 10.4088/Jcp.12M07642  1
2012 Kahn PV, Walker TM, Williams TS, Cornblatt BA, Mohs RC, Keefe RS. Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study. Schizophrenia Research. 142: 153-8. PMID 23040735 DOI: 10.1016/j.schres.2012.09.009  1
2012 Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings of the National Academy of Sciences of the United States of America. 109: E2657-64. PMID 22927402 DOI: 10.1073/Pnas.1206820109  1
2012 Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, Awad AG, Keefe RS, Naber D. Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation. Patient Preference and Adherence. 6: 521-32. PMID 22879738 DOI: 10.2147/PPA.S25635  1
2012 Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, George Awad A, Keefe RS, Naber D. Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. Psychiatry Research. 200: 835-42. PMID 22841345 DOI: 10.1016/j.psychres.2012.05.005  1
2012 Keefe RS, Vinogradov S, Medalia A, Buckley PF, Caroff SN, D'Souza DC, Harvey PD, Graham KA, Hamer RM, Marder SM, Miller DD, Olson SJ, Patel JK, Velligan D, Walker TM, et al. Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. The Journal of Clinical Psychiatry. 73: 1016-22. PMID 22687548 DOI: 10.4088/Jcp.11M07100  1
2012 Weiser M, Gershon AA, Rubinstein K, Petcu C, Ladea M, Sima D, Podea D, Keefe RS, Davis JM. A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research. 138: 35-8. PMID 22483162 DOI: 10.1016/j.schres.2012.02.014  0.01
2012 Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophrenia Research. 136: 25-31. PMID 22169248 DOI: 10.1016/J.Schres.2011.11.001  1
2012 Rosenheck R, Swartz M, McEvoy J, Stroup TS, Davis S, Keefe RS, Hsiao J, Lieberman J. Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics & Outcomes Research. 7: 103-11. PMID 20528436 DOI: 10.1586/14737167.7.2.103  0.01
2012 Johnson EB, Wilson J, Poh J, Yaakub S, Dorairaj K, Rapisarda A, Chee M, Chong SA, Subramaniam M, Keefe R, Kraus M, Keong JLC, Bong YL, Adcock RA. Midbrain modulation of hippocampus dependent learning in Singaporeans at ultra high risk for the development of schizophrenia F1000research. 3. DOI: 10.7490/F1000Research.1090638.1  1
2012 Keefe RSE, Kraus MS. Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia American Journal of Psychiatry. 169: 354-357. DOI: 10.1176/appi.ajp.2012.12010042  1
2012 Krishnan RR, Fivaz M, Kraus MS, Keefe RSE. Hierarchical temporal processing deficit model of reality distortion and psychoses (Molecular Psychiatry (2011) 16, (129-144) DOI: 10.1038/mp.2010.63) Molecular Psychiatry. 17: 470. DOI: 10.1038/mp.2011.54  1
2012 Uchida H, Sakurai H, Bies RR, Stroup S, Keefe RS, Suzuki T, Tsuboi T, Mimura M, Pollock BG, Mamo DC. Poster #218 DOPAMINE D2 RECEPTOR OCCUPANCY AND COGNITION IN SCHIZOPHRENIA: ANALYSIS OF THE CATIE DATA Schizophrenia Research. 136: S359. DOI: 10.1016/S0920-9964(12)71050-2  0.01
2012 Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M. Poster #199 CLINICAL TRIALS OF POTENTIAL COGNITIVE-ENHANCING DRUGS IN SCHIZOPHRENIA: WHAT HAVE WE LEARNED SO FAR? Schizophrenia Research. 136: S352. DOI: 10.1016/S0920-9964(12)71031-9  0.01
2012 Lee l, Rapisarda A, Kraus M, Chong S, Keefe R. Poster #79 LONGITUDINAL YOUTH-AT-RISK STUDY (LYRIKS): EXAMINING THE PRODROME FROM ANOTHER PERSPECTIVE Schizophrenia Research. 136. DOI: 10.1016/S0920-9964(12)70912-X  1
2012 Colijn MA, Barbato M, Keefe RS, Perkins DO, Woods SW, Addington J. Poster #143 AT RISK FOR PSYCHOSIS: THE ROLE OF COGNITION Schizophrenia Research. 136: S237. DOI: 10.1016/S0920-9964(12)70715-6  0.01
2012 Rapisarda A, Lim T, Lim M, Collinson S, Kraus M, Keefe R. Poster #163 APPLICABILITY OF THE MATRICS CONSENSUS COGNITIVE BATTERY IN SINGAPORE Schizophrenia Research. 136. DOI: 10.1016/S0920-9964(12)70477-2  1
2012 Joyce E, Keefe R. NEUROIMAGING Schizophrenia Research. 136: S87. DOI: 10.1016/S0920-9964(12)70308-0  0.01
2012 Joyce E, Keefe R. Neuropsychology And Development Schizophrenia Research. 136. DOI: 10.1016/S0920-9964(12)70299-2  0.01
2012 Harvey PD, Ruse S, Davis V, Solomon M, Keefe R. 14:30 COMPUTERIZED FUNCTIONAL CAPACITY ASSESSMENTIN SCHIZOPHRENIA: EVIDENCE FOR CONVERGENT VALIDITY Schizophrenia Research. 136: S78-S79. DOI: 10.1016/S0920-9964(12)70284-0  0.08
2012 Supina D, Endicott J, Madhoo M, Keefe R, Trivedi M, Wu J, Scheckner B, Lasser R. PMH61 Effects of Lisdexamfetamine Dimesylate Augmentation on Functional Outcomes in Adults with Partially or Fully Remitted Major Depressive Disorder Value in Health. 15: A93. DOI: 10.1016/J.JVAL.2012.03.506  0.01
2011 Chong SA, Campbell A, Chee M, Liu J, Marx C, McGorry P, Subramaniam M, Yung A, Keefe RS. The Singapore flagship programme in translational and clinical research in psychosis. Early Intervention in Psychiatry. 5: 290-300. PMID 22032547 DOI: 10.1111/J.1751-7893.2011.00304.X  1
2011 Kerfoot KE, Rosenheck RA, Petrakis IL, Swartz MS, Keefe RSE, McEvoy JP, Stroup TS. Substance use and schizophrenia: Adverse correlates in the CATIE study sample Schizophrenia Research. 132: 177-182. PMID 21872443 DOI: 10.1016/j.schres.2011.07.032  1
2011 Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. The American Journal of Psychiatry. 168: 831-9. PMID 21572163 DOI: 10.1176/Appi.Ajp.2011.08121844  1
2011 Sim K, Lee J, Subramaniam M, Liu JJ, Keefe R, Zhang XD, Lee TS, Chong SA. Integrated genetic and genomic approach in the SingaporeTranslational and Clinical Research in Psychosis Study: an overview. Early Intervention in Psychiatry. 5: 91-9. PMID 21535421 DOI: 10.1111/J.1751-7893.2011.00272.X  1
2011 Burdick KE, Goldberg TE, Cornblatt BA, Keefe RS, Gopin CB, Derosse P, Braga RJ, Malhotra AK. The MATRICS consensus cognitive battery in patients with bipolar I disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 1587-92. PMID 21451499 DOI: 10.1038/Npp.2011.36  1
2011 Krishnan RR, Kraus MS, Keefe RSE. Comprehensive model of how reality distortion and symptoms occur in schizophrenia: Could impairment in learning-dependent predictive perception account for the manifestations of schizophrenia? Psychiatry and Clinical Neurosciences. 65: 305-317. PMID 21447049 DOI: 10.1111/j.1440-1819.2011.02203.x  1
2011 Reise SP, Ventura J, Keefe RS, Baade LE, Gold JM, Green MF, Kern RS, Mesholam-Gately R, Nuechterlein KH, Seidman LJ, Bilder R. Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia. Psychological Assessment. 23: 245-61. PMID 21381848 DOI: 10.1037/A0021501  1
2011 Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophrenia Research. 127: 188-94. PMID 21277745 DOI: 10.1016/J.Schres.2011.01.004  0.04
2011 Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RS. Methodological issues in negative symptom trials. Schizophrenia Bulletin. 37: 250-4. PMID 21270473 DOI: 10.1093/schbul/sbq161  1
2011 Krishnan RR, Fivaz M, Kraus MS, Keefe RS. Hierarchical temporal processing deficit model of reality distortion and psychoses. Molecular Psychiatry. 16: 129-44. PMID 21263440 DOI: 10.1038/mp.2010.63  0.01
2011 Kern RS, Gold JM, Dickinson D, Green MF, Nuechterlein KH, Baade LE, Keefe RS, Mesholam-Gately RI, Seidman LJ, Lee C, Sugar CA, Marder SR. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophrenia Research. 126: 124-31. PMID 21159492 DOI: 10.1016/J.Schres.2010.11.008  1
2011 Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biological Psychiatry. 69: 442-9. PMID 21145041 DOI: 10.1016/J.Biopsych.2010.09.052  1
2011 Keefe RSE, Kraus MS, Krishnan RR. Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia Neuropsychopharmacology. 36: 367-368. PMID 21116261 DOI: 10.1038/npp.2010.153  1
2011 Greenberg G, Rosenheck RA, Erickson SK, Desai RA, Stefanovics EA, Swartz M, Keefe RS, McEvoy J, Stroup TS. Criminal justice system involvement among people with schizophrenia. Community Mental Health Journal. 47: 727-36. PMID 21113799 DOI: 10.1007/s10597-010-9362-9  1
2011 McClay JL, Adkins DE, Aberg K, Bukszár J, Khachane AN, Keefe RS, Perkins DO, McEvoy JP, Stroup TS, Vann RE, Beardsley PM, Lieberman JA, Sullivan PF, van den Oord EJ. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 616-26. PMID 21107309 DOI: 10.1038/Npp.2010.193  1
2011 Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, Campbell EC, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, Lieberman JA. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. The Journal of Clinical Psychiatry. 72: 295-303. PMID 20816031 DOI: 10.4088/Jcp.09M05793Yel  1
2011 Segarra N, Bernardo M, Gutierrez F, Justicia A, Fernadez-Egea E, Allas M, Safont G, Contreras F, Gascon J, Soler-Insa PA, Menchon JM, Junque C, Keefe RSE. Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls European Psychiatry. 26: 69-73. PMID 20435446 DOI: 10.1016/J.Eurpsy.2009.11.001  0.01
2011 Sachs G, Winklbaur B, Jagsch R, Keefe RS. Validation of the German version of the brief assessment of cognition in Schizophrenia (BACS) - preliminary results. European Psychiatry : the Journal of the Association of European Psychiatrists. 26: 74-7. PMID 20427153 DOI: 10.1016/j.eurpsy.2009.10.006  1
2011 Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophrenia Bulletin. 37: 1209-17. PMID 20410237 DOI: 10.1093/Schbul/Sbq038  1
2011 Keefe RS, Vinogradov S, Medalia A, Silverstein SM, Bell MD, Dickinson D, Ventura J, Marder SR, Stroup TS. Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophrenia Bulletin. 37: 1057-65. PMID 20194249 DOI: 10.1093/Schbul/Sbq010  1
2011 Hurford IM, Marder SR, Keefe RS, Reise SP, Bilder RM. A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophrenia Bulletin. 37: 538-45. PMID 19776205 DOI: 10.1093/Schbul/Sbp095  1
2011 Keefe RS. Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 7: 22-8. PMID 18458774 DOI: 10.1002/j.2051-5545.2008.tb00142.x  0.01
2011 Sarkisyan G, Gurovich I, Keefe R. Normative data for Russian population and standardization of the scale “Brief assessment of cognition in schizophrenia” European Psychiatry. 26: 434-434. DOI: 10.1016/S0924-9338(11)72141-1  0.01
2010 Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophrenia Research. 125: 161-8. PMID 21075600 DOI: 10.1016/J.Schres.2010.09.015  0.08
2010 Lamonica HM, Keefe RS, Harvey PD, Gold JM, Goldberg TE. Differential effects of emotional information on interference task performance across the life span. Frontiers in Aging Neuroscience. 2. PMID 20953250 DOI: 10.3389/Fnagi.2010.00141  1
2010 Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 71: 1475-81. PMID 20816042 DOI: 10.4088/JCP.09m05950gry  1
2010 Ascher-Svanum H, Nyhuis AW, Stauffer V, Kinon BJ, Faries DE, Phillips GA, Schuh K, Awad AG, Keefe R, Naber D. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Current Medical Research and Opinion. 26: 2403-10. PMID 20812791 DOI: 10.1185/03007995.2010.515900  1
2010 Chan WY, Yang GL, Chia MY, Woon PS, Lee J, Keefe R, Sitoh YY, Nowinski WL, Sim K. Cortical and subcortical white matter abnormalities in adults with remitted first-episode mania revealed by Tract-Based Spatial Statistics. Bipolar Disorders. 12: 383-9. PMID 20636635 DOI: 10.1111/J.1399-5618.2010.00829.X  1
2010 Ventura J, Reise SP, Keefe RS, Baade LE, Gold JM, Green MF, Kern RS, Mesholam-Gately R, Nuechterlein KH, Seidman LJ, Bilder RM. The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition. Schizophrenia Research. 121: 24-31. PMID 20542412 DOI: 10.1016/J.Schres.2010.04.016  1
2010 Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, Hawkins K, Heaton R, ... Keefe RS, et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Archives of General Psychiatry. 67: 578-88. PMID 20530007 DOI: 10.1016/J.Schres.2010.02.210  1
2010 Konneker TI, Crowley JJ, Quackenbush CR, Keefe RS, Perkins DO, Stroup TS, Lieberman JA, van den Oord E, Sullivan PF. No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 1115-7. PMID 20468059 DOI: 10.1002/Ajmg.B.31077  1
2010 Chia MY, Chan WY, Chua KY, Lee H, Lee J, Lee R, Lim C, Tay E, Woon PS, Keefe RS, Sim K. The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia. Psychiatry Research. 178: 33-8. PMID 20451258 DOI: 10.1016/j.psychres.2010.03.020  1
2010 Polanczyk G, Moffitt TE, Arseneault L, Cannon M, Ambler A, Keefe RS, Houts R, Odgers CL, Caspi A. Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort. Archives of General Psychiatry. 67: 328-38. PMID 20368509 DOI: 10.1001/Archgenpsychiatry.2010.14  1
2010 Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD. Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 35: 1053-62. PMID 20090669 DOI: 10.1038/Npp.2009.211  1
2010 Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RS, Murray RM, Poulton R, Moffitt TE. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. The American Journal of Psychiatry. 167: 160-9. PMID 20048021 DOI: 10.1176/Appi.Ajp.2009.09040574  1
2010 Barch DM, Keefe RS. Anticipating DSM-V: opportunities and challenges for cognition and psychosis. Schizophrenia Bulletin. 36: 43-7. PMID 19923191 DOI: 10.1093/schbul/sbp139  1
2010 Keefe RSE. Neurocognition Antipsychotic Trials in Schizophrenia: the Catie Project. 97-119. DOI: 10.1017/CBO9780511712265.007  1
2010 Keefe R, Vinogradov S, Medalia A, Buckley P, Caroff S, D'Souza D, Harvey P, Graham K, Marder S, Miller D, Olson S, Patel J, Velligan D, Walker T, Haim A, et al. Feasibility Study Of Multi-Site Cognitive Remediation In The Schizophrenia Trials Network (Crstn) Schizophrenia Research. 117: 394-394. DOI: 10.1016/J.Schres.2010.02.712  1
2010 Kern RS, Gold JM, Dickinson D, Green MF, Nuechterlein KH, Keefe RS, Marder SR, Sugar CA. COGNITIVE DYSFUNCTION AND COMMUNITY FUNCTIONING IN SCHIZOPHRENIA: RESULTS FROM THE MATRICS PSYCHOMETRIC AND STANDARDIZATION STUDY (PASS) Schizophrenia Research. 117: 323-324. DOI: 10.1016/J.Schres.2010.02.551  0.01
2010 Geffen Y, Anand R, Keefe R, Davidson M. Results Of Phase 2B Eagle Trial; A Double Blind Placebo Control Study Evaluating The Efficacy And Safety Of Bl-1020, A Gaba Enhanced Antipsychotic For The Treatment Of Schizophrenia Schizophrenia Research. 117: 212-212. DOI: 10.1016/J.Schres.2010.02.296  1
2010 Reichenberg A, Caspi A, Harrington H, Houts R, Keefe R, Murray R, Poulton R, Moffitt T. Static And Dynamic Cognitive Deficits In Childhood Precede Adult Schizophrenia: A 30-Year Study Schizophrenia Research. 117: 175-175. DOI: 10.1016/J.Schres.2010.02.207  1
2010 Volovyk SV, Keefe RS. UNIQUE OPPORTUNITY FOR COHERENT INSIGHTS INTO THE NATURE OF EARTH/SPACE NATURAL RADIATION EFFECTS ON MAN'S BRAIN DISORDERS Schizophrenia Research. 117: 530-531. DOI: 10.1016/j.schres.2010.02.1024  0.04
2010 Buchanan RW, Barch D, Csernansky J, Goff D, Gold J, Jarskog F, Javitt D, Keefe R, Lieberman J, McEvoy J, McMahon R, Marder S. MK-0777 FOR THE TREATMENT OF COGNITIVE IMPAIRMENTS IN PEOPLE WITH SCHIZOPHRENIA Schizophrenia Research. 117: 119. DOI: 10.1016/J.Schres.2010.02.053  0.01
2010 Carpenter W, Hofer A, Keefe R, Mueser K, Naber D, Chen E. Dsm-V: New Paradigms And Other Controversies Schizophrenia Research. 117: 110-110. DOI: 10.1016/J.Schres.2010.02.025  1
2009 Penn DL, Keefe RS, Davis SM, Meyer PS, Perkins DO, Losardo D, Lieberman JA. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research. 115: 17-23. PMID 19766459 DOI: 10.1016/J.Schres.2009.08.016  1
2009 Lipkovich IA, Deberdt W, Csernansky JG, Sabbe B, Keefe RS, Kollack-Walker S. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. Bmc Psychiatry. 9: 44. PMID 19602273 DOI: 10.1186/1471-244X-9-44  1
2009 Kraus MS, Keefe RSE, Krishnan RKR. Memory-prediction errors and their consequences in schizophrenia Neuropsychology Review. 19: 336-352. PMID 19575296 DOI: 10.1007/s11065-009-9106-1  1
2009 Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). The American Journal of Psychiatry. 166: 675-82. PMID 19369319 DOI: 10.1176/Appi.Ajp.2008.08060806  1
2009 Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, Bradford DW, Strauss JL, Naylor JC, Payne VM, Lieberman JA, Savitz AJ, Leimone LA, Dunn L, Porcu P, Morrow AL, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 1885-903. PMID 19339966 DOI: 10.1038/Npp.2009.26  1
2009 Sim K, Yang GL, Loh D, Poon LY, Sitoh YY, Verma S, Keefe R, Collinson S, Chong SA, Heckers S, Nowinski W, Pantelis C. White matter abnormalities and neurocognitive deficits associated with the passivity phenomenon in schizophrenia: a diffusion tensor imaging study. Psychiatry Research. 172: 121-7. PMID 19297135 DOI: 10.1016/J.Pscychresns.2009.02.003  1
2009 Krishnan RR, Keefe R, Kraus M. Schizophrenia is a disorder of higher order hierarchical processing Medical Hypotheses. 72: 740-744. PMID 19231093 DOI: 10.1016/J.Mehy.2008.12.039  1
2009 Need AC, Ge D, Weale ME, Maia J, Feng S, Heinzen EL, Shianna KV, Yoon W, KasperaviciÅ«te D, Gennarelli M, Strittmatter WJ, Bonvicini C, Rossi G, Jayathilake K, Cola PA, ... ... Keefe RS, et al. A genome-wide investigation of SNPs and CNVs in schizophrenia. Plos Genetics. 5: e1000373. PMID 19197363 DOI: 10.1371/Journal.Pgen.1000373  1
2009 Need AC, Keefe RSE, Ge D, Grossman I, Dickson S, McEvoy JP, Goldstein DB. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. European Journal of Human Genetics. 17: 946-957. PMID 19156168 DOI: 10.1038/Ejhg.2008.264  1
2009 Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research. 107: 1-12. PMID 19027269 DOI: 10.1016/J.Schres.2008.10.011  1
2009 Kern RS, Green MF, Nuechterlein KH, Keefe RS. CMINDS does not have identical tests to the CATIE and MATRICS batteries. Commentary on O'Halloran et al. Schizophrenia Research. 107: 327-9; author reply . PMID 19013770 DOI: 10.1016/J.Schres.2008.10.015  1
2009 Kleinman L, Lieberman J, Dube S, Mohs R, Zhao Y, Kinon B, Carpenter W, Harvey PD, Green MF, Keefe RS, Frank L, Bowman L, Revicki DA. Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophrenia Research. 107: 275-85. PMID 19013769 DOI: 10.1016/J.Schres.2008.10.002  1
2009 Harvey PD, Keefe RS, Patterson TL, Heaton RK, Bowie CR. Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. Journal of Clinical and Experimental Neuropsychology. 31: 462-71. PMID 18720182 DOI: 10.1080/13803390802251386  1
2009 Need AC, Ge D, Weale ME, Maia J, Feng S, Heinzen EL, Shianna KV, Yoon W, Kasperavičiūtė D, Gennarelli M, Strittmatter WJ, Bonvicini C, Rossi G, Jayathilake K, Cola PA, ... ... Keefe RSE, et al. Correction: A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia Plos Genetics. 5. DOI: 10.1371/Annotation/E0196Ebb-De40-453F-8F8C-791B126618Da  0.01
2009 Pinheiro AP, Keefe RSE, Skelly T, Olarte M, Leviel K, Lange LA, Lange EM, Stroup TS, Lieberman J, Sullivan PF. Erratum: Rates of depressive and anxiety disorders in a residential mother-infant unit for unsettled infants (Australian and New Zealand Journal of Psychiatry (2007) 41 (836-842)) Australian and New Zealand Journal of Psychiatry. 43. DOI: 10.1080/00048670903270266  1
2009 Pinheiro AP, Keefe RSE, Skelly T, Olarte M, Leviel K, Lange LA, Lange EM, Stroup TS, Lieberman J, Sullivan Pf. Erratum: AKT1 and neurocognition in schizophrenia (Australian and New Zealand Journal of Psychiatry (2007) 41 (169-177)) Australian and New Zealand Journal of Psychiatry. 43. DOI: 10.1080/00048670903228991  1
2008 Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, Lieberman JA. Extrapyramidal side-effects of antipsychotics in a randomised trial. The British Journal of Psychiatry : the Journal of Mental Science. 193: 279-88. PMID 18827289 DOI: 10.1192/Bjp.Bp.108.050088  1
2008 Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, Callahan J, Zipursky RB, Perkins DO, Tohen M, Breier A, McGlashan TH. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research. 105: 1-9. PMID 18774696 DOI: 10.1016/J.Schres.2008.07.008  1
2008 Keefe RSE, Harvey PD. Implementation considerations for multisite clinical trials with cognitive neuroscience tasks Schizophrenia Bulletin. 34: 656-663. PMID 18495645 DOI: 10.1093/Schbul/Sbn042  1
2008 Keefe RSE, Harvey PD, Goldberg TE, Gold JM, Walker TM, Kennel C, Hawkins K. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS) Schizophrenia Research. 102: 108-115. PMID 18495435 DOI: 10.1016/J.Schres.2008.03.024  1
2008 Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA. What CATIE found: results from the schizophrenia trial. Psychiatric Services (Washington, D.C.). 59: 500-6. PMID 18451005 DOI: 10.1176/Ps.2008.59.5.500  1
2008 Lieberman JA, Drake RE, Sederer LI, Belger A, Keefe R, Perkins D, Stroup S. Science and recovery in schizophrenia. Psychiatric Services (Washington, D.C.). 59: 487-96. PMID 18451003 DOI: 10.1176/Ps.2008.59.5.487  1
2008 Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS. Relationship of cognition and psychopathology to functional impairment in schizophrenia. The American Journal of Psychiatry. 165: 978-87. PMID 18450928 DOI: 10.1176/Appi.Ajp.2008.07111713  1
2008 Crowley JJ, Keefe RS, Perkins DO, Stroup TS, Lieberman JA, Sullivan PF. The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 147: 1298-300. PMID 18286587 DOI: 10.1002/Ajmg.B.30727  1
2008 Hill SK, Sweeney JA, Hamer RM, Keefe RS, Perkins DO, Gu H, McEvoy JP, Lieberman JA. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. Journal of the International Neuropsychological Society : Jins. 14: 209-21. PMID 18282319 DOI: 10.1017/S1355617708080570  1
2008 Resnick SG, Rosenheck RA, Canive JM, De Souza C, Stroup TS, McEvoy J, Davis S, Keefe RS, Swartz M, Lieberman J. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. The Journal of Behavioral Health Services & Research. 35: 215-25. PMID 18246429 DOI: 10.1007/S11414-007-9101-3  1
2008 Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. The American Journal of Psychiatry. 165: 203-13. PMID 18172019 DOI: 10.1176/Appi.Ajp.2007.07010042  1
2008 Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. The American Journal of Psychiatry. 165: 214-20. PMID 18172018 DOI: 10.1176/Appi.Ajp.2007.07010043  1
2008 Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Seidman LJ, Stover E, Marder SR. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. The American Journal of Psychiatry. 165: 221-8. PMID 18172017 DOI: 10.1176/Appi.Ajp.2007.07010089  1
2008 Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 1217-28. PMID 17625502 DOI: 10.1038/Sj.Npp.1301499  1
2008 Bratti I, Ventura J, Marder S, Reise S, Keefe R, Bilder R. PRACTICE AND LEARNING EFFECTS WITH NEUROPSYCHOLOGICAL BATTERIES IN PATIENTS WITH SCHIZOPHRENIA Schizophrenia Research. 102: 117. DOI: 10.1016/S0920-9964(08)70354-2  0.01
2008 Keefe R. The Cognitive Effects Of Risperidone, Olanzapine And Quetiapine In Patients With First Episode Psychosis Schizophrenia Research. 102: 54. DOI: 10.1016/S0920-9964(08)70170-1  0.01
2008 Stroup S, Lieberman J, McEvoy J, Swartz M, Davis S, Rosenheck R, Keefe R. Findings Of Phase 3 Of The Catie Schizophrenia Trial Schizophrenia Research. 102: 34-35. DOI: 10.1016/S0920-9964(08)70109-9  1
2008 Keefe R. Neurocognitive Task Performance As An Outcome Measure In Antipsychotic Treatment Trials Schizophrenia Research. 102: 4. DOI: 10.1016/S0920-9964(08)70014-8  0.01
2007 Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry and Clinical Neurosciences. 61: 602-609. PMID 18081619 DOI: 10.1111/J.1440-1819.2007.01725.X  0.01
2007 Kraus MS, Keefe RSE. Cognition as an outcome measure in schizophrenia British Journal of Psychiatry. 191. PMID 18019044 DOI: 10.1192/bjp.191.50.s46  1
2007 Goff DC, Keefe R, Citrome L, Davy K, Krystal JH, Large C, Thompson TR, Volavka J, Webster EL. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. Journal of Clinical Psychopharmacology. 27: 582-9. PMID 18004124 DOI: 10.1097/Jcp.0B013E31815Abf34  1
2007 Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. The American Journal of Psychiatry. 164: 1061-71. PMID 17606658 DOI: 10.1176/Ajp.2007.164.7.1061  1
2007 Keefe RSE, Fenton WS. How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophrenia Bulletin. 33: 912-920. PMID 17567627 DOI: 10.1093/schbul/sbm046  1
2007 Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry. 64: 633-47. PMID 17548746 DOI: 10.1001/Archpsyc.64.6.633  1
2007 Pinheiro AP, Keefe RS, Skelly T, Olarte M, Leviel K, Lange LA, Lange EM, Stroup TS, Lieberman J, Sullivan PF. AKT1 and neurocognition in schizophrenia. The Australian and New Zealand Journal of Psychiatry. 41: 169-77. PMID 17464696 DOI: 10.1080/00048670601109956  1
2007 Bralet MC, Falissard B, Neveu X, Lucas-Ross M, Eskenazi AM, Keefe RS. Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients. European Psychiatry : the Journal of the Association of European Psychiatrists. 22: 365-70. PMID 17434715 DOI: 10.1016/j.eurpsy.2007.02.001  0.01
2007 Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American Journal of Psychiatry. 164: 428-36. PMID 17329467 DOI: 10.1176/Ajp.2007.164.3.428  1
2007 Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. The American Journal of Psychiatry. 164: 415-27. PMID 17329466 DOI: 10.1176/Ajp.2007.164.3.415  1
2007 Pandina GJ, Bilder R, Harvey PD, Keefe RSE, Aman MG, Gharabawi G. Risperidone and Cognitive Function in Children With Disruptive Behavior Disorders Biological Psychiatry. 62: 226-234. PMID 17210137 DOI: 10.1016/J.Biopsych.2006.09.036  1
2007 Sullivan PF, Keefe RS, Lange LA, Lange EM, Stroup TS, Lieberman J, Maness PF. NCAM1 and neurocognition in schizophrenia. Biological Psychiatry. 61: 902-10. PMID 17161382 DOI: 10.1016/J.Biopsych.2006.07.036  1
2007 Keefe RSE, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Dr. Keefe and colleagues reply American Journal of Psychiatry. 164: 1911-1912. DOI: 10.1176/Appi.Ajp.2007.07071086R  1
2007 Lipkovich I, Kollack-Walker S, Kinon B, Stauffer V, Ascher-Svanum H, Keefe R. Poster Abstract #3: Cognitive Status of Patients With Schizophrenia as Modulator or Mediator of Functional Outcome Neurotherapeutics. 4: 725-726. DOI: 10.1016/J.Nurt.2007.03.007  1
2007 VanDenburgh AM, Abu-Shakra S, Brin MF, Beddingfield F, Lipkovich I, Houston JP, Ahl J, Kollack-Walker S, Kinon B, Stauffer V, Ascher-Svanum H, Keefe R, Byrnes KR, Stoica B, Faden AI, et al. Abstracts from the ASENT 2007 Annual Meeting March 5–8, 2007 Neurotherapeutics. 4: 725-731. DOI: 10.1016/J.Nurt.2007.03.005  1
2006 Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. The American Journal of Psychiatry. 163: 2080-9. PMID 17151158 DOI: 10.1176/Ajp.2006.163.12.2080  1
2006 Keefe RS, Perkins DO, Gu H, Zipursky RB, Christensen BK, Lieberman JA. A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophrenia Research. 88: 26-35. PMID 16930949 DOI: 10.1016/J.Schres.2006.06.041  1
2006 Chwastiak LA, Rosenheck RA, McEvoy JP, Keefe RS, Swartz MS, Lieberman JA. Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatric Services (Washington, D.C.). 57: 1102-9. PMID 16870960 DOI: 10.1176/Ps.2006.57.8.1102  0.01
2006 Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, Tapp A, Keefe RS, Rosenheck RA. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatric Services (Washington, D.C.). 57: 1094-101. PMID 16870959 DOI: 10.1176/PS.2006.57.8.1094  1
2006 McEvoy JP, Johnson J, Perkins D, Lieberman JA, Hamer RM, Keefe RS, Tohen M, Glick ID, Sharma T. Insight in first-episode psychosis. Psychological Medicine. 36: 1385-93. PMID 16740175 DOI: 10.1017/S0033291706007793  0.01
2006 Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 2033-46. PMID 16641947 DOI: 10.1038/Sj.Npp.1301072  1
2006 Woodward TS, Menon M, Hu X, Keefe RS. Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring. Schizophrenia Research. 85: 106-12. PMID 16626938 DOI: 10.1016/J.Schres.2006.03.008  1
2006 Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. The American Journal of Psychiatry. 163: 611-22. PMID 16585435 DOI: 10.1176/Appi.Ajp.163.4.611  1
2006 McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American Journal of Psychiatry. 163: 600-10. PMID 16585434 DOI: 10.1176/Appi.Ajp.163.4.600  1
2006 Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, Green AI, Glick IB, Kahn RS, Sharma T, Tohen M, McEvoy JP, Weiden PJ, Lieberman JA. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophrenia Research. 83: 53-63. PMID 16529910 DOI: 10.1016/J.Schres.2005.10.016  1
2006 Keefe RS, Poe M, Walker TM, Kang JW, Harvey PD. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. The American Journal of Psychiatry. 163: 426-32. PMID 16513863 DOI: 10.1176/Appi.Ajp.163.3.426  1
2006 Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsiao JK, Lieberman J. Barriers to employment for people with schizophrenia. The American Journal of Psychiatry. 163: 411-7. PMID 16513861 DOI: 10.1176/Appi.Ajp.163.3.411  0.01
2006 Keefe RS, Poe M, Walker TM, Harvey PD. The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome. Journal of Clinical and Experimental Neuropsychology. 28: 260-9. PMID 16484097 DOI: 10.1080/13803390500360539  1
2006 Rosenheck R, Stroup S, Keefe RS, McEvoy J, Swartz M, Perkins D, Hsiao J, Shumway M, Lieberman J. Measuring outcome priorities and preferences in people with schizophrenia. The British Journal of Psychiatry : the Journal of Mental Science. 187: 529-36. PMID 16319405 DOI: 10.1192/Bjp.187.6.529  0.01
2006 Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophrenia Research. 81: 1-15. PMID 16202565 DOI: 10.1016/J.Schres.2005.07.038  1
2006 Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Rock SL, Woolson S, Tohen M, Tollefson GD, Sanger TM, Lieberman JA. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biological Psychiatry. 59: 97-105. PMID 16140282 DOI: 10.1016/J.Biopsych.2005.06.022  1
2006 Chwastiak LA, Rosenheck RA, McEvoy JP, Keefe RS, Swartz MS, Lieberman JA. Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatric Services. 57: 1102-1109. DOI: 10.1176/Appi.Ps.57.8.1102  1
2006 Lieberman JA, Stroup TS, McEVOY JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Hsiao J, Severe J, Lebowitz BD. Dr. Lieberman and Colleagues Reply American Journal of Psychiatry. 163: 555-556. DOI: 10.1176/Appi.Ajp.163.3.555-A  1
2006 Keefe R. C.07.02 Neurocognitive efficacy in patients with chronic schizophrenia European Neuropsychopharmacology. 16: S577. DOI: 10.1016/S0924-977X(06)70830-6  0.04
2006 Atkins AS, Khan A, Kelly SE, Abraham C, Ulshen D, Plassman BL, Welsh-Bohmer KA, Keefe RS. P4-340: PERFORMANCE-BASED ASSESSMENT OF IADL FUNCTIONING IN MCI AND MILD AD USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT): A PILOT STUDY Alzheimer's & Dementia. 14: P1597-P1597. DOI: 10.1016/J.Jalz.2018.07.163  0.04
2005 Narendran R, Frankle WG, Keefe R, Gil R, Martinez D, Slifstein M, Kegeles LS, Talbot PS, Huang Y, Hwang DR, Khenissi L, Cooper TB, Laruelle M, Abi-Dargham A. Altered prefrontal dopaminergic function in chronic recreational ketamine users. The American Journal of Psychiatry. 162: 2352-9. PMID 16330601 DOI: 10.1176/Appi.Ajp.162.12.2352  0.01
2005 Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, Kim S, Keefe R, Manschreck T, McEvoy J, Lieberman J. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research. 80: 1-8. PMID 16182516 DOI: 10.1016/J.Schres.2005.08.007  1
2005 Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine. 353: 1209-23. PMID 16172203 DOI: 10.1056/Nejmoa051688  1
2005 Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RS, Rosenheck RA, Stroup TS, Lieberman JA. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research. 80: 33-43. PMID 16171976 DOI: 10.1016/J.Schres.2005.07.034  1
2005 Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe RS, Stroup TS, Lieberman JA. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research. 80: 9-18. PMID 16125372 DOI: 10.1016/J.Schres.2005.07.015  1
2005 Artiola I Fortuny L, Garolera M, Hermosillo Romo D, Feldman E, Fernández Barillas H, Keefe R, Lemaître MJ, Ortiz Martín A, Mirsky A, Monguió I, Morote G, Parchment S, Parchment LJ, Da Pena E, Politis DG, et al. Research with spanish-speaking populations in the United States: lost in the translation. A commentary and a plea. Journal of Clinical and Experimental Neuropsychology. 27: 555-64. PMID 16019632 DOI: 10.1080/13803390490918282  1
2005 Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, Lieberman JA, Glick I, Patel JK. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophrenia Research. 78: 161-9. PMID 15950436 DOI: 10.1016/J.Schres.2005.04.017  1
2005 Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC, Nuechterlein KH, Laughren T, Levin R, Stover E, Fenton W, Marder SR. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin. 31: 5-19. PMID 15888422 DOI: 10.1093/Schbul/Sbi020  1
2005 Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry. 62: 361-70. PMID 15809403 DOI: 10.1001/Archpsyc.62.4.361  1
2005 Keefe RSE, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia Biological Psychiatry. 57: 688-691. PMID 15780858 DOI: 10.1016/j.biopsych.2005.01.003  1
2004 Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry. 56: 301-7. PMID 15336511 DOI: 10.1016/J.Biopsych.2004.06.023  1
2004 Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. The American Journal of Psychiatry. 161: 985-95. PMID 15169686 DOI: 10.1176/Appi.Ajp.161.6.985  1
2004 Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research. 68: 283-97. PMID 15099610 DOI: 10.1016/J.Schres.2003.09.011  1
2004 Harvey PD, Green MF, Keefe RS, Velligan DI. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. The Journal of Clinical Psychiatry. 65: 361-72. PMID 15096076 DOI: 10.4088/Jcp.V65N0312  1
2004 Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipurksy R, Woods SW, Miller TJ, Marquez E, Breier A, McGlashan TH. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophrenia Research. 67: 115-22. PMID 14984870 DOI: 10.1016/J.Schres.2003.08.007  1
2004 Sethuraman G, Ahmed S, Rock S, Young C, Marquez E, Purdon S, Keefe R. P.2.137 Can the PANSS cognitive factor be a validsurrogate for neurocognon in schizophrenia? European Neuropsychopharmacology. 14: S292-S293. DOI: 10.1016/S0924-977X(04)80357-2  0.01
2003 Keefe RS, Mohs RC, Bilder RM, Harvey PD, Green MF, Meltzer HY, Gold JM, Sano M. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophrenia Bulletin. 29: 45-55. PMID 12908660 DOI: 10.1093/Oxfordjournals.Schbul.A006990  1
2003 Keefe RSE, Poe MP, McEvoy JP, Vaughan A. Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications Psychopharmacology. 169: 383-389. PMID 12759802 DOI: 10.1007/s00213-003-1476-0  1
2003 Morey RA, Emberger K, Inan S, McClure R, Lieberman J, Keefe R, McCarthy G, Belger A. Functional MRI assessment of atypical and conventional antipsychotic effects on cognitive function in schizophrenia patients Schizophrenia Research. 60: 229. DOI: 10.1016/S0920-9964(03)81212-4  1
2003 Keefe R, Seidman L, Christensen B, Hamer R, Yurgelun-Todd D, Lewine R, Sitskoorn M, Sharma T, Tohen M, Lieberman J. Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis Schizophrenia Research. 60: 289. DOI: 10.1016/S0920-9964(03)80477-2  0.01
2003 Breier A, Keefe RS, Young CA, Purdon SE, Gold JM, Davis KL. A one-year double-blind comparison of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in patients with schizophrenia Schizophrenia Research. 60: 274-275. DOI: 10.1016/S0920-9964(03)80434-6  1
2003 Yurgelun-Todd D, Renshaw P, Wei H, Keefe R, Charles H, Tohen M, Liebermann J. Improved attention is associated with reductions in frontal lobe lactate levels in first episode psychosis Schizophrenia Research. 60: 318. DOI: 10.1016/S0920-9964(03)80271-2  0.01
2003 Hawkins KA, McGlashan T, Keefe R, Christensen B, Addington J, Marquez E, Breier A. Neuropsychological status of the first-episode prodrome Schizophrenia Research. 60: 4. DOI: 10.1016/S0920-9964(03)80008-7  1
2002 Keefe RS, Arnold MC, Bayen UJ, McEvoy JP, Wilson WH. Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources. Schizophrenia Research. 57: 51-67. PMID 12165376 DOI: 10.1016/S0920-9964(01)00306-1  1
2002 Conway CR, Bollini AM, Graham BG, Keefe RS, Schiffman SS, McEvoy JP. Sensory acuity and reasoning in delusional disorder. Comprehensive Psychiatry. 43: 175-8. PMID 11994833 DOI: 10.1053/comp.2002.32358  1
2002 Keefe R. Compliance, cognition and psychosis: first episode European Psychiatry. 17: 12. DOI: 10.1016/S0924-9338(02)80056-6  0.12
2001 Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment American Journal of Psychiatry. 158: 176-184. PMID 11156796 DOI: 10.1176/Appi.Ajp.158.2.176  1
2000 Bollini AM, Arnold MC, Keefe RS. Test-retest reliability of the dot test of visuospatial working memory in patients with schizophrenia and controls. Schizophrenia Research. 45: 169-73. PMID 10978884 DOI: 10.1016/S0920-9964(99)00216-9  1
2000 Roitman SE, Mitropoulou V, Keefe RS, Silverman JM, Serby M, Harvey PD, Reynolds DA, Mohs RC, Siever LJ. Visuospatial working memory in schizotypal personality disorder patients. Schizophrenia Research. 41: 447-55. PMID 10728721 DOI: 10.1016/S0920-9964(99)00085-7  1
1999 Keefe RS, Arnold MC, Bayen UJ, Harvey PD. Source monitoring deficits in patients with schizophrenia; a multinomial modelling analysis. Psychological Medicine. 29: 903-14. PMID 10473317 DOI: 10.1017/S0033291799008673  1
1999 Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis Schizophrenia Bulletin. 25: 201-222. PMID 10416727 DOI: 10.1093/Oxfordjournals.Schbul.A033374  1
1999 Keefe RSE, Bollini AM, Silva SG. Do Novel Antipsychotics Improve Cognition? A Report of a Meta-Analysis Psychiatric Annals. 29: 623-629. DOI: 10.3928/0048-5713-19991101-08  0.01
1998 Davis KL, Buchsbaum MS, Shihabuddin L, Spiegel-Cohen J, Metzger M, Frecska E, Keefe RS, Powchik P. Ventricular enlargement in poor-outcome schizophrenia. Biological Psychiatry. 43: 783-93. PMID 9611667 DOI: 10.1016/S0006-3223(97)00553-2  1
1998 Keefe R, Courtney M, Bayan U, Harvey P, McEvoy J. Does autonoetic agnosia underlie specific psychotic symptoms in schizophrenia? Schizophrenia Research. 29: 36. DOI: 10.1016/S0920-9964(97)88379-X  0.01
1997 Vocisano C, Klein DN, Keefe RSE. Lifetime comorbidity, lifetime history of psychosis and suicide attempts, and current symptoms of patients with deteriorated affective disorder Psychiatry Research. 73: 33-45. PMID 9463837 DOI: 10.1016/S0165-1781(97)00114-5  1
1997 Keefe RSE, Lees-Roitman SE, Dupre RL. Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay Schizophrenia Research. 26: 9-14. PMID 9376341 DOI: 10.1016/S0920-9964(97)00037-6  1
1997 Roitman SE, Keefe RS, Harvey PD, Siever LJ, Mohs RC. Attentional and eye tracking deficits correlate with negative symptoms in schizophrenia. Schizophrenia Research. 26: 139-46. PMID 9323344 DOI: 10.1016/S0920-9964(97)00044-3  1
1997 Roitman SE, Cornblatt BA, Bergman A, Obuchowski M, Mitropoulou V, Keefe RS, Silverman JM, Siever LJ. Attentional functioning in schizotypal personality disorder. The American Journal of Psychiatry. 154: 655-60. PMID 9137121 DOI: 10.1176/AJP.154.5.655  0.04
1997 Keefe RS, Silverman JM, Mohs RC, Siever LJ, Harvey PD, Friedman L, Roitman SE, DuPre RL, Smith CJ, Schmeidler J, Davis KL. Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia. Archives of General Psychiatry. 54: 169-76. PMID 9040285 DOI: 10.1001/Archpsyc.1997.01830140081014  1
1997 Harvey PD, Keefe RSE. Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment Cns Spectrums. 2: 41-55. DOI: 10.1017/S1092852900005034  1
1997 Harvey PD, Keefe RSE. Cognitive Impairment in Schizophrenia and Implications of Atypical Neuroleptic Treatment Cns Spectrums. 2: 41-55. DOI: 10.1017/S1092852900005034  0.12
1997 Keefe RS, Courtney M, McEvoy JM. Self-monitoring deficits in schizophrenia: Autonoetic agnosia Schizophrenia Research. 24: 110. DOI: 10.1016/S0920-9964(97)82306-7  0.01
1996 Harvey PD, Davidson M, White L, Keefe RS, Hirschowitz J, Mohs RC, Davis KL. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. Biological Psychiatry. 40: 755-60. PMID 8894068 DOI: 10.1016/0006-3223(95)00486-6  1
1996 Epstein JI, Keefe RS, Roitman SL, Harvey PD, Mohs RC. Impact of neuroleptic medications on continuous performance test measures in schizophrenia. Biological Psychiatry. 39: 902-5. PMID 8860194 DOI: 10.1016/0006-3223(95)00588-9  1
1996 Siegel BV, Trestman RL, O'Flaithbheartaigh S, Mitropoulou V, Amin F, Kirrane R, Silverman J, Schmeidler J, Keefe RS, Siever LJ. D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder. Schizophrenia Research. 20: 29-32. PMID 8794491 DOI: 10.1016/0920-9964(95)00002-X  0.01
1996 Trestman RL, Keefe RS, Mitropoulou V, Harvey PD, deVegvar ML, Lees-Roitman S, Davidson M, Aronson A, Silverman J, Siever LJ. Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Research. 59: 127-36. PMID 8771227 DOI: 10.1016/0165-1781(95)02709-2  0.2
1996 Keefe RS, Frescka E, Apter SH, Davidson M, Macaluso JM, Hirschowitz J, Davis KL. Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. The American Journal of Psychiatry. 153: 806-11. PMID 8633694 DOI: 10.1176/Ajp.153.6.806  1
1996 Vocisano C, Klein DN, Keefe RS, Dienst ER, Kincaid MM. Demographics, family history, premorbid functioning, developmental characteristics, and course of patients with deteriorated affective disorder. The American Journal of Psychiatry. 153: 248-55. PMID 8561207 DOI: 10.1176/Ajp.153.2.248  1
1996 Keefe RSE, Cornblatt BA. Schizophrenia: All Pathways to Symptoms Pass Through Cognitive Deficits? Contemporary Psychology: a Journal of Reviews. 41: 900-902. DOI: 10.1037/003129  0.04
1996 Keefe R, Roitman S, Dupre R, Harvey P. Laboratory and clinical tests of spatial working memory Schizophrenia Research. 18: 208-209. DOI: 10.1016/0920-9964(96)85644-1  0.01
1996 Harvey PD, Keefe RSE, Mitroupolou V, DuPre R, Roitman SL, Mohs RC, Siever LJ. Information-processing markers of vulnerability to schizophrenia: Performance of patients with schizotypal and nonschizotypal personality disorders Psychiatry Research. 60: 49-56. DOI: 10.1016/0165-1781(95)02764-5  1
1996 Lees Roitman S, Keefe R, Dupre R, Siever L. Visuospatial working memory in schizotypal personality disorder Biological Psychiatry. 39: 577. DOI: 10.1016/0006-3223(96)84211-9  0.04
1995 Keefe RS, Roitman SE, Harvey PD, Blum CS, DuPre RL, Prieto DM, Davidson M, Davis KL. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophrenia Research. 17: 25-33. PMID 8541247 DOI: 10.1016/0920-9964(95)00027-J  1
1995 Davidson M, Keefe RSE. Cognitive impairment as a target for pharmacological treatment in schizophrenia Schizophrenia Research. 17: 123-129. PMID 8541245 DOI: 10.1016/0920-9964(95)00037-M  1
1995 Davidson M, Harvey PD, Powchik P, Parrella M, White L, Knobler HY, Losonczy MF, Keefe RS, Katz S, Frecska E. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. The American Journal of Psychiatry. 152: 197-207. PMID 7840352 DOI: 10.1176/Ajp.152.2.197  0.24
1995 Keefe RSE. The contribution of neuropsychology to psychiatry American Journal of Psychiatry. 152: 6-15. PMID 7802121 DOI: 10.1176/AJP.152.1.6  1
1995 Yehuda R, Keefe RS, Harvey PD, Levengood RA, Gerber DK, Geni J, Siever LJ. Learning and memory in combat veterans with posttraumatic stress disorder. The American Journal of Psychiatry. 152: 137-9. PMID 7802106 DOI: 10.1176/Ajp.152.1.137  1
1995 Keefe R. Progress in Experimental Personality and Psychopathology Research, vol. 15 American Journal of Psychiatry. 152: 288-289. DOI: 10.1176/Ajp.152.2.288  0.01
1995 Keefe RS, Lees Roitman S, Dupre RL, Harvey PD, Davis KL, Mohs RC. The relationship between working memory deficits and other measures sensitive to prefrontal dysfunction Schizophrenia Research. 15: 123. DOI: 10.1016/0920-9964(95)95378-M  0.12
1995 Siever LJ, Trestman RL, Siegel BV, Losonczy M, Mitropoulou V, Silverman J, Keefe R, Mohs R, Buchsbaum M, Davis KL. Neuroimaging, neurobiological, and neuropsychological abnormalities in SPD: Implications for a model of the schizophrenia spectrum Schizophrenia Research. 15: 99. DOI: 10.1016/0920-9964(95)95307-U  1
1995 White L, Parrella M, Harvey PD, Keefe R, Davidson M. Influence of neuroleptics on symptom structure in schizophrenia Schizophrenia Research. 15: 23-24. DOI: 10.1016/0920-9964(95)95086-O  0.04
1994 Siever LJ, Friedman L, Moskowitz J, Mitropoulou V, Keefe R, Roitman SL, Merhige D, Trestman R, Silverman J, Mohs R. Eye movement impairment and schizotypal psychopathology. American Journal of Psychiatry. 151: 1209-1215. PMID 8037257 DOI: 10.1176/Ajp.151.8.1209  1
1994 Keefe RS, Silverman JM, Roitman SE, Harvey PD, Duncan MA, Alroy D, Siever LJ, Davis KL, Mohs RC. Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests. Psychiatry Research. 53: 1-12. PMID 7991726 DOI: 10.1016/0165-1781(94)90091-4  1
1994 Kahn RS, Harvey PD, Davidson M, Keefe RS, Apter S, Neale JM, Mohs RC, Davis KL. Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophrenia Research. 11: 217-24. PMID 7514887 DOI: 10.1016/0920-9964(94)90015-9  1
1994 Frecska E, Losonczy M, Keefe R, Apter S, Davidson M, Mohs R, Davis K. Age dependent change of ventricular measures in schizophrenia: Cross-sectional analysis Biological Psychiatry. 35: 704-705. DOI: 10.1016/0006-3223(94)90980-6  0.01
1994 Apter S, Keefe R, Hirschowitz J, Davidson M, Macaluso J, Amato R, Davis K. Longitudinal classification in schizophrenia: The relationship between kraepelinian and deficit syndrome subtypologies Biological Psychiatry. 35: 695. DOI: 10.1016/0006-3223(94)90944-X  0.01
1994 Epstein J, Keefe R, Lees Roitman S, Harvey P, Davidson M, Siever L, Mohs R. Neuroleptic effects on CPT and eye tracking in schizophrenia Biological Psychiatry. 35: 674. DOI: 10.1016/0006-3223(94)90872-9  0.01
1994 Cornblatt B, Obuchowski M, Schnur D, O'Brien J, Reich M, Wolf L, Futrovsky L, Keefe R, Osgood G. Adolescent-onset psychosis and the schizophrenia spectrum Biological Psychiatry. 35: 660. DOI: 10.1016/0006-3223(94)90821-4  0.01
1994 Keefe R, Blum C, Roitman S, Harvey P, Davidson M, Mohs R, Davis K. Working memory dysfunction in Kraepelinian schizophrenics Biological Psychiatry. 35: 660. DOI: 10.1016/0006-3223(94)90820-6  0.01
1993 Siever LJ, Kalus OF, Keefe RS. The Boundaries of Schizophrenia Psychiatric Clinics of North America. 16: 217-244. DOI: 10.1016/S0193-953X(18)30171-0  0.01
1993 Frecska E, Losonczy M, Keefe R, Silverman J, Davidson M, Davis K. The characteristics of poor outcome, ‘Kraepelinian’ schizophrenia European Neuropsychopharmacology. 3: 400. DOI: 10.1016/0924-977X(93)90193-P  0.04
1993 Siever L, Trestman R, Amin F, Keefe R, Knott P, Silverman J. The biology of schizotypy Schizophrenia Research. 9: 227. DOI: 10.1016/0920-9964(93)90499-9  0.01
1993 Keefe R, Lees S, Merhige D, Blum C, Harvey P, Davis K, Mohs R. Visuospatial working memory deficits in schizophrenia Schizophrenia Research. 9: 179-180. DOI: 10.1016/0920-9964(93)90355-M  0.01
1992 Keefe RS, Harvey PD, Lenzenweger MF, Davidson M, Apter SH, Schmeidler J, Mohs RC, Davis KL. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms. Psychiatry Research. 44: 153-65. PMID 1480680 DOI: 10.1016/0165-1781(92)90049-9  1
1992 Harvey PD, Lenzenweger MF, Keefe RS, Pogge DL, Serper MR, Mohs RC. Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients: formal thought disorder. Psychiatry Research. 44: 141-51. PMID 1480679 DOI: 10.1016/0165-1781(92)90048-8  1
1992 Davidson M, Kahn RS, Stern RG, Harvey PD, Keefe R, Knott P, Apter S, Webster L, Davis KL. Measurements of plasma homovanillic acid in schizophrenic patients. Clinical Neuropharmacology. 521A-522A. PMID 1354058 DOI: 10.1097/00002826-199201001-00271  0.16
1992 Frecska E, Losonczy MF, Keefe RSE, Silverman JM, Davidson M, Davis KL. Characteristics Of Poor Outcome Schizophrenia Clinical Neuropharmacology. 15. DOI: 10.1097/00002826-199202001-00170  1
1991 Keefe RS, Lobel DS, Mohs RC, Silverman JM, Harvey PD, Davidson M, Losonczy MF, Davis KL. Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms. Schizophrenia Research. 4: 71-9. PMID 2039764 DOI: 10.1016/0920-9964(91)90026-N  1
1991 Keefe RS, Silverman JM, Siever LJ, Cornblatt BA. Refining phenotype characterization in genetic linkage studies of schizophrenia Social Biology. 38: 197-218. PMID 1801201 DOI: 10.1080/19485565.1991.9988788  1
1991 SIEVER LJ, KEEFE R, BERNSTEIN DP, COCCARO EF, KLAR HM, ZEMISHLANY Z, PETERSON A, DAVIDSON M, MAHON T, HORVATH T, MOHS R. Dr. Siever and Colleagues Reply American Journal of Psychiatry. 148: 1097-1097. DOI: 10.1176/Ajp.148.8.1097  0.01
1991 Cornblatt BA, Keefe RSE. The genetics of mental illness: An overview Biodemography and Social Biology. 38: 1-5. DOI: 10.1080/19485565.1991.9988784  0.01
1991 Harvey P, Davidson M, Mohs R, Keefe R, Moskowitz J, Knott P, Duffelmeyer M. Plasma HVA correlates of attentional performance in unmedicated schizophrenics Schizophrenia Research. 4: 345-346. DOI: 10.1016/0920-9964(91)90258-S  0.04
1991 Frecska E, Losonczy M, Keefe R, Silverman J, Davidson M, Harvey P, McQueeney R, Lobel D, Apter S, Davis K. Kraepelinian schizophrenia: A replication in an independent sample Schizophrenia Research. 4: 257. DOI: 10.1016/0920-9964(91)90108-4  0.01
1990 Siever LJ, Silverman JM, Horvath TB, Klar H, Coccaro E, Keefe RS, Pinkham L, Rinaldi P, Mohs RC, Davis KL. Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients. Archives of General Psychiatry. 47: 634-40. PMID 2360857 DOI: 10.1001/Archpsyc.1990.01810190034005  1
1990 Siever LJ, Keefe R, Bernstein DP, Coccaro EF, Klar HM, Zemishlany Z, Peterson AE, Davidson M, Mahon T, Horvath T, Mohs R. Eye tracking impairment in clinically identified patients with schizotypal personality disorder American Journal of Psychiatry. 147: 740-745. PMID 2343917 DOI: 10.1176/Ajp.147.6.740  1
1990 Harvey PD, Keefe RS, Moskowitz J, Putnam KM, Mohs RC, Davis KL. Attentional markers of vulnerability to schizophrenia: performance of medicated and unmedicated patients and normals. Psychiatry Research. 33: 179-88. PMID 2243895 DOI: 10.1016/0165-1781(90)90072-D  0.88
1989 Keefe RS, Mohs RC, Losonczy MF, Davidson M, Silverman JM, Horvath TB, Davis KL. Premorbid sociosexual functioning and long-term outcome in schizophrenia. The American Journal of Psychiatry. 146: 206-11. PMID 2912262 DOI: 10.1176/AJP.146.2.206  1
1989 Keefe RS, Siever LJ, Mohs RC, Peterson AE, Mahon TR, Bergman RL, Davis KL. Eye tracking, schizophrenic symptoms, and schizotypal personality disorder. European Archives of Psychiatry and Neurological Sciences. 239: 39-42. PMID 2792157 DOI: 10.1007/BF01739742  1
1989 Silverman JM, Keefe RSE, Mohs RC, Davis KL. A study of the reliability of the family history method in genetic studies of Alzheimer disease. Alzheimer Disease & Associated Disorders. 3: 218-223. DOI: 10.1097/00002093-198900000-00004  1
1989 Silverman JM, Mohs RC, Siever LJ, Keefe RSE, Schear S, Davis KL. Using family history screening for linkage studies in schizophrenia Biological Psychiatry. 25. DOI: 10.1016/0006-3223(89)91776-9  1
1989 Siever LJ, Coccaro EF, Silverman J, Keefe R, Klar H, Davis KL. Biologic markers for personality disorders: A dimensional approach Biological Psychiatry. 25: A140. DOI: 10.1016/0006-3223(89)91769-1  0.01
1989 Keefe RS, Harvey PD, Bergman R, Mohs RC, Davis KL. State and trait components of negative symptoms within schizophrenic patients Biological Psychiatry. 25: A105. DOI: 10.1016/0006-3223(89)91698-3  0.16
1989 Keefe RSE, Siever LJ, Silverman JM, Mohs RC, Davis KL. symptom correlates of poor eye tracking in patients with schizotypal personality disorder and relatives of schizophrenic probands Biological Psychiatry. 25. DOI: 10.1016/0006-3223(89)91693-4  1
1989 Keefe RSE, Mohs RC, Siever LJ, Silverman JM, Harvey PD, Brenin DS, Davis KL. Relations among eye tracking, CPT, and backward masking deficits in schizophrenic patients and their relatives Biological Psychiatry. 25. DOI: 10.1016/0006-3223(89)91692-2  1
1987 Silverman JM, Mohs RC, Davidson M, Losonczy MF, Keefe RS, Breitner JC, Sorokin JE, Davis KL. Familial schizophrenia and treatment response. The American Journal of Psychiatry. 144: 1271-6. PMID 3661762 DOI: 10.1176/Ajp.144.10.1271  1
1987 Keefe RS, Mohs RC, Losonczy MF, Davidson M, Silverman JM, Kendler KS, Horvath TB, Nora R, Davis KL. Characteristics of very poor outcome schizophrenia. The American Journal of Psychiatry. 144: 889-95. PMID 3605400 DOI: 10.1176/Ajp.144.7.889  1
1987 Davidson M, Keefe RS, Mohs RC, Siever LJ, Losonczy MF, Horvath TB, Davis KL. L-dopa challenge and relapse in schizophrenia. The American Journal of Psychiatry. 144: 934-8. PMID 2886063 DOI: 10.1176/AJP.144.7.934  1
Show low-probability matches.